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TRANSCATHETER AORTIC VALVE IMPLANTATION: CURRENT STATUS ANd 
CHALLENgES TO IMPROVE OUTCOMES
Degenerative severe aortic valve stenosis is a frequent valvular disease affecting 3% of 
patients aged>75 years and its prevalence is expected to increase.(1) Elderly patients with 
symptomatic severe aortic stenosis have poor outcFome if medically treated, whereas 
surgical aortic valve replacement reduces the 1-year mortality rates significantly.(2,3) 
However, at least 30% of symptomatic severe aortic stenosis patients are considered 
of excessive surgical risk and are not referred to or are denied for surgical treatment.
(4) Balloon aortic valvulotomy is associated with limited clinical improvement, does 
not show any prognostic improvement and is associated with high rate of recurrence 
of aortic stenosis (80% at 1 year follow up).(5,6) Transcatheter aortic valve implantation 
(TAVI) has been an important therapeutic breakthrough for patients with symptomatic 
severe aortic stenosis and contraindications for surgical aortic valve replacement.
The first-in-human TAVI was successfully performed in 2002, in a critically ill patient with 
severe aortic stenosis in whom previous balloon valvulotomy had failed.(7) The prosthesis 
device and implantation technique were further developed and the results of the cohort 
B Placement of Aortic TraNscathetER Valves (PARTNER) trial demonstrated that TAVI is a 
safe and effective treatment for patients with symptomatic severe aortic stenosis and 
contraindications for surgery, improving the outcome of these patients compared with 
patients who were conventionally treated (medically or with balloon aortic valvulotomy): 
1 year mortality 30.7% vs. 50.7%, respectively.(8) Subsequently, the Food and Drug Ad-
ministration approved TAVI as an alternative to surgical aortic valve replacement for non-
operable patients. The results of the cohort A PARTNER trial, randomizing patients with 
severe aortic stenosis and high operative risk to TAVI or surgical aortic valve replacement 
demonstrated that TAVI was also safe in this subgroup of patients and led to comparable 
outcomes at follow-up (1-year mortality: 24.2% with TAVI vs. 26.8% with surgical treat-
ment).(9) The results of these randomized trials and the numerous national registries have 
established TAVI as a safe and feasible alternative for patients with symptomatic severe 
aortic stenosis who are non-surgical candidates or have high surgical risk. Furthermore, 
TAVI is currently included in the 2012 European Society of Cardiology guidelines for the 
management of patients with symptomatic severe aortic stenosis and contraindications 
or high-risk for surgery, with class IB and IIa B indications, respectively.(10)
However, TAVI is also associated with complications. The rate of stroke was higher in 
the group of patients treated with TAVI compared with surgically treated group.(8,11) 
Moreover paravalvular aortic regurgitation (AR) was more frequently observed in TAVI 
compared to surgically treated patients, having important prognostic implications since 
moderate and severe paravalvular AR were related to increased mortality at follow-up.
(11) Patients treated with TAVI also showed a higher rate of new conduction abnormalities 
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and pacemaker implantation compared with surgically treated patients.(12) A number of 
additional complications of this relatively new procedure that may affect the clinical 
course of patients were also acknowledged: perioperative myocardial infarction, acute 
kidney injury, pericardial effusion, vascular and bleeding complications.(13)
The patient characteristics are one of the main determinants of the risk of procedural 
complications. The rate of the observed complications may also differ between trans-
Table 1. Transcathter aortic valve devices
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catheter aortic valve manufacturers. Currently, the balloon-expandable Edwards SAPIEN 
(Edwards SAPIEN or SAPIEN XT, Edwards Lifescience, Irvine, CA) and the self-expandable 
CoreValve (CoreValve system, Medtronic, Minneapolis, MN) are widely commercially 
available although a plethora of new designs have been clinically studied (Table 1).(14)
The Edwards SAPIEN valve can be implanted both through transfemoral and trans-
apical access whereas the CoreValve system is implanted mainly through transarterial 
access (transfemoral, transsubclavian, transaxillary or direct transaortic). The design of 
the frames has undergone several modifications in order to optimize its deployment in 
the aortic root and avoid related complications. The optimal recommended deployment 
of the frame is not easy to achieve and a shallow or deep implantation of the valve in 
the left ventricular outflow tract may be observed, which may increase the risk of acute 
coronary ostia occlusion, paravalvular regurgitation or prosthesis migration.(15) In addi-
tion, it is acknowledged that some complications may be expected more frequently in 
specific transcatheter valve designs. For example, in patients treated with the CoreValve 
device, pacemaker implantation is more frequent compared with patients treated with 
the Edwards SAPIEN valve.(14)
It is becoming apparent that in order to optimize the management of TAVI candidates 
there should be an emphasis on careful selection of patients that will benefit most from 
this procedure, in combination with an effort to minimize procedural complications that 
influence their post-operative clinical course. Consequently, understanding the patho-
physiology of TAVI complications and defining the outcome of specific high risk groups 
may be of clinical importance.
EMERgINg ROLE OF MULTI-dETECTOR ROw COMPUTEd TOMOgRAPHy TO 
PREdICT OUTCOMES IN PATIENTS UNdERgOINg TRANSCATHETER AORTIC 
VALVE IMPLANTATION
Multi-detector row computed tomography (MDCT) is an important imaging technique 
to evaluate patients with symptomatic severe aortic stenosis who are candidates for 
TAVI. The superb spatial resolution of this imaging technique permits accurate sizing of 
the aortic annulus, key to select the most appropriate transcatheter valve size. Studies 
have shown that the choice of valve size based on MDCT measurements, as opposed to 
echocardiography or angiography measurements, has led to less postoperative paraval-
vular AR and therefore MDCT is emerging as the ‘’gold standard’’ method for valve sizing 
in patients undergoing TAVI (Figure 1). (16)
MDCT is also used to asses dimensions of various components of the aortic root such 
as the height of the coronary ostia relative to the aortic annulus, and moreover it can be 
used to clarify the size and morphology of the peripheral arteries (ilio-femoral arterial 
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system), assisting the decision for the appropriate the procedural access (transfemoral, 
transarterial or transapical) (Figure 1).(17)
The use of post-operative MDCT has also shed light into many procedural related 
complications in TAVI patients. Optimal expansion of the frames has been evaluated 
with MDCT and interestingly under-expanded frames may be found in 8% of patients 
which has been related with significant paravalvular AR and prosthesis migration.(18) 
The pathophysiology of paravalvular AR has also been investigated with post-operative 
MDCT.(17) Moreover, post-operative MDCT studies have shown that deep implantation 
of the frame in the left ventricular outflow tract may be responsible for new conduction 
disorders after TAVI.(19) In a few patients with perioperative coronary ostia occlusion 
successfully treated with immediate percutaneous coronary artery intervention MDCT 
has also revealed the possibility of direct impingement of the coronary ostia by the 
frame.(20)
Figure 1. Multi-detector row computed tomography may give critical information in patients undergo-
ing transcatheter aortic valve implantation. The transverse plane of the native aortic annulus (Panel A, red 
line) is reconstructed and detailed measurements of the aortic annulus dimensions are used for accurate 
valve sizing (Panels B, E, F).The morphology of the aortic valve (tricuspid or bicuspid) can be defined with 
accuracy (Panel C).The distance between the native annulus and the coronary ostia can be also evaluated 
(Panels D and G). Moreover computed tomography provides information about calcification, tortuosity and 
stenosis of iliofemoral arteries, identifying patients who are eligible for transfemoral access (Panels H, I, J, K).
Abbreviations: D: diameter, LM: left main, RCA: right coronary artery.
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PREdICTION OF OUTCOME IN SPECIFIC POPULATIONS
In real-world clinical practice, patients with symptomatic severe aortic stenosis that do 
not strictly fulfil the inclusion criteria of PARTNER trial (cohort A and B) may receive a so 
called ‘’off–label” treatment with TAVI. These patients are deemed at excessive surgical 
risk and TAVI may be a last resource treatment.
Indeed, TAVI may be a successful alternative treatment, with acceptable rate of 
in-hospital and long-term mortality rates, in patients with pure native aortic valve re-
gurgitation deemed inoperable.(21) Moreover, patients with concomitant severe aortic 
stenosis and severe mitral regurgitation may receive TAVI treatment, although generally 
these cases were excluded from large randomized trials.(22) TAVI may reduce concomi-
tant mitral regurgitation in this group. However, it remains unclear how to identify the 
patients that will show an improvement in mitral regurgitation after TAVI.(22)
Registries have also shown low complication rates and acceptable survival for high-
risk patients with failing bioprosthesis treated with transcatheter valve-in-valve.(23) 
However, so far there has not been a direct comparison with a similar group of high risk 
patients undergoing surgical treatment (Figure 2).
Figure 2. Transcatheter aortic valve implantation may have an “off- label” use for failing bioprtosthetic 
valves. Successful implantation of a 23 mm Edwards SAPIEN valve in a failing 23 mm Carpentier Edwards 
PERIMOUNT aortic bioprosthesis.
ObjECTIVES ANd OUTLINE OF THE THESIS
The objective of this thesis was to investigate the role of MDCT to predict outcomes 
in patients undergoing TAVI and also to focus on the outcome of specific populations 
undergoing this procedure.
In part I, the role of MDCT to predict the occurrence of procedural complications will 
be evaluated, focusing on the combination of pre- and post-procedural MDCT for the 
definition of the underlying mechanisms of complications such as paravalvular regurgi-
tation (Chapter 2) or new onset rhythm conduction disturbances (Chapter 3). Addition-
16 Chapter 1
ally, the deployment of the frame in relation to the coronary ostia will be systemati-
cally studied with post-operative MDCT and its implications for percutaneous coronary 
interventions at follow-up will be carefully addressed (Chapter 4). The combination of 
pre- and post-procedural MDCT images in addition to echocardiography measurements 
may also help us better identify the prevalence of late pericardial effusion in patients 
treated with TAVI (Chapter 5). Patients undergoing transfemoral TAVI do not experience 
pleuro-pericardial surgical trauma and they are expected to develop less frequently late 
pericardial effusion as compared with patients treated with transapical TAVI.
In part II the outcomes of specific populations undergoing TAVI will be studied. The 
predictive value of valvuloarterial impedance (ZVa) will be tested in patients undergoing 
TAVI (chapter 6). Ideally high baseline ZVa values would help us to identify a subgroup 
of patients with poor outcome, and this measurement could be included in future TAVI 
risk scores. Patients with more than mild mitral regurgitation represent also a special 
subgroup of interest (Chapter 7). There are few studies investigating predictors of mitral 
regurgitation improvement post-TAVI and they are based only in semiquantitative 
methods for grading mitral regurgitation severity. Patients with significant baseline 
mitral regurgitation will be followed up to 12 months after the procedure. Quantitative 
measurements of baseline mitral regurgitation severity will be evaluated for their ability 
to predict post-operative mitral regurgitation improvement. Finally, the subgroup of 
patients with failing bioprostheses treated with TAVI will be investigated (Chapter 8). 
The long-term survival of these patients will be compared with the survival of patients 
with similar surgical risk undergoing valvular redo surgery.
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AbSTRACT
background: Multidetector row computed tomography (MDCT) assessment of aortic 
annulus dimensions and frame position and deployment have been associated with 
paravalvular aortic regurgitation (PAVR) after transcatheter aortic valve implantation 
(TAVI). The present evaluation investigated the (pre- and post-procedure) MDCT asso-
ciates of PAVR≥2+. Methods: In total, 123 patients referred for TAVI underwent clinical 
evaluation, transthoracic echocardiography and pre- and post-TAVI MDCT. Pre-TAVI 
MDCT measurements of the aortic annular dimensions and post-TAVI MDCT evaluation 
of the position and deployment of the prosthesis in the native annulus were performed. 
Results: At 1 month follow-up, PAVR≥2+ was observed in 25 (20.3%) patients. The dif-
ference between the MDCT derived maximum diameter of the aortic annulus and the 
nominal diameter of the implanted prosthesis (OR 1.912, p=0.002) and shallow position 
of the frame in the LVOT (<2mm) (OR 4.865, p=0.017) were independently related to 
significant PAVR. A maximum annulus diameter ≥2 mm larger than the nominal frame 
diameter had 72% sensitivity and 61% specificity to predict PAVR. Conclusion: In pa-
tients undergoing TAVI, ≥2 mm difference between maximum aortic annulus diameter 
and nominal prosthesis diameter, as well as depth of the frame into the LVOT <2mm are 
independently associated with PAVR≥2+.
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INTROdUCTION
Transcatheter aortic valve implantation (TAVI) is an established alternative for patients 
with severe aortic stenosis and high operative risk mortality or contraindications for 
surgical aortic valve replacement.(1-3) Paravalvular aortic regurgitation (PAVR) remains 
still as one of the main concerns of this therapy since the prognostic implications of 
PAVR are not negligible and data from the PARTNER cohort B trial have shown a two-fold 
increased mortality among patients with mild or more PAVR compared with patients 
showing none or trace PAVR.(4)
Determinants of PAVR are still debated. Of particular importance is the measurement 
of aortic valve annular dimensions with 3-dimensional imaging techniques such as 
multidetector row computed tomography (MDCT) since relative undersizing of the 
transcatheter prosthesis has been related to increased incidence of PAVR.(5-7) In ad-
dition, position and deployment of the prosthesis have been suggested as relevant 
underlying mechanisms of PAVR after TAVI.(7-9) However, few studies have demon-
strated the relevance of post-procedural MDCT to identify the determinants of PAVR 
after TAVI. Accordingly, the present study aimed to identify the MDCT-derived pre- and 
post-procedural parameters independently associated with significant PAVR after TAVI.
METHOdS
Patients with symptomatic severe aortic stenosis and high risk or contraindications for 
surgical aortic valve replacement were evaluated for TAVI. A heart team consisting of 
clinical, imaging and interventional cardiologists, cardiac surgeons and anesthesiologists 
agreed on the indication for TAVI following the European Society of Cardiology and the 
European Association of Cardio-Thoracic Surgery guidelines.(10) Prior to TAVI, all patients 
underwent clinical evaluation, including estimation of the operative risk based on logistic 
EuroSCORE, (11) comprehensive thansthoracic echocardiography (TTE) to estimate the 
aortic stenosis severity, MDCT to size the aortic annulus and evaluate the anatomy and 
dimensions of the peripheral arteries, and invasive coronary angiography to exclude sig-
nificant coronary artery disease amenable to percutaneous intervention. One month after 
TAVI, TTE was used to assess the prosthetic valve function, whereas the deployment and 
position of the prosthetic valve were evaluated on MDCT. The pre- and post-procedural 
MDCT data on aortic root anatomy and geometry and apposition of the prosthetic valve 
within the native aortic annulus were related to the presence of significant PAVR after TAVI. 
Clinical, echocardiographic and MDCT data were prospectively collected in an electronic 
clinical patient file (EPD vision version 8.3.3.6; Leiden, The Netherlands) and retrospec-
tively analyzed. The institutional review board approved this retrospective analysis.
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TAVI was performed at the hybrid operating room under general anesthesia. Fluo-
roscopy was the mainstay imaging technique to guide the procedure assisted by trans-
esophageal echocardiography (iE33, Philips Medical System, Andover, MA, USA). A 23-, 
26- or 29-mm Edwards Sapien and Sapien XT valve (Edwards Lifesciences, Irvine, CA) was 
implanted based on the dimensions of the aortic annulus. The transfemoral approach 
was the preferred delivery technique whereas the transapical approach was performed 
in patients with non-suitable peripheral artery anatomy or in patients in whom a 29-
mm valve was implanted.(12) During rapid right ventricular pacing, aortic valve balloon 
dilatation was performed and subsequently the balloon-expandable prosthesis valve 
was deployed.(12) The presence of significant PAVR was evaluated with transesophageal 
echocardiography and re-ballooning of the prosthesis or valve-in-valve were performed 
as bail-out techniques to reduce aortic regurgitation severity. Patients who underwent a 
valve-in-valve procedure were excluded from further analysis.
A commercialy available ultrasound system (Vivid 7, E9, General Electric Horten, 
Norway) was used for pre- and post-TAVI TTE. The pre-procedural evaluation included 
the assessment of the valve morphology at the parasternal short-axis view, and the 
left ventricular outflow tract (LVOT) diameter was measured at the parasternal long-
axis view.(13) The peak and mean transaortic pressure gradients were assessed in the 
apical long-axis or 5-chamber views and the aortic valve area was calculated with the 
continuity equation.(13) Aortic stenosis was considered severe if aortic valve area was 
<1.0 cm2 and/or the transaortic mean gradient was ≥40 mmHg.(14) LV end-diastolic and 
end-systolic volumes were calculated with the Simpson’s method and LV ejection frac-
tion was derived.(15)
In order to evaluate the presence of PAVR after TAVI, color-flow Doppler echocar-
diography was performed after optimization of Nyquist limit and gain settings. PAVR 
was evaluated on multiple echocardiographic views and conventional criteria such as 
the vena contracta width, the ratio of the regurgitant jet width to the LVOT diameter, 
pressure half-time and the proportion of the circumference of the sewing ring occupied 
by the regurgitant jet were used to estimate the PAVR (0 absent, 1+ trace or mild, 2+ 
mild-to-moderate, 3+ moderate-to-severe and 4+ severe).(16, 17) PAVR ≥2+ at the first 
post-operative month was considered significant.
All patients underwent pre- and post-TAVI MDCT of the aortic root using either a 
64- or a 320-detector row computed tomography scanner (Aquilion64, Toshiba Medi-
cal Systems, Otawara, Japan and Aquilion ONE, Toshiba Medical Systems, Tochigi-ken, 
Japan). With the Acquilion 64 system, the data was acquired with a collimation of 64x0.5 
mm and a gantry rotation time of 400 ms whereas the tube current was 300-400 mA 
and the voltage was 120 kV or 135 kV, depending on body mass index of the patients. 
With the Acquilion ONE system, the data was acquired with a collimation of 320x0.5 mm, 
gantry rotation time of 350 ms and tube current and voltage set at 400-580 mA and 100 
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kV, 120 kV or 135 kV (based on body mass index of the patients), respectively. Unless 
contraindicated, patients received beta-blockers if their heart rate was ≥70 beats per 
minute. All scans were performed during mid-inspiratory breath-hold and 80-90 mL of 
non-ionic contrast (Iomeron 400, Bracco, Milan, Italy) was injected into the antecubital 
vein. Subsequently, data sets were reconstructed and off-line post-processing of MDCT 
images was performed on dedicated workstations (Vitrea2, Vital Images, Minneapolis, 
Minnesota, USA).
Diastolic and systolic images of the aortic root at the respective 75% and 30-40% of RR 
interval were selected. By aligning the three orthogonal multiplanar reformation planes, 
the double-oblique transversal plane that bisects the aortic annulus beneath the hinge 
points of the aortic cusps was obtained. At this level, the minimum and maximum aortic 
annulus diameters and the annulus area were measured. From the orthogonal sagittal 
and coronal views, the aortic annulus diameters were also measured as previously de-
scribed.(18) In addition, from the non-contrast enhanced images, the calcium Agatston 
score of the aortic valve and landing zone was calculated. On 1-month follow-up MDCT 
scans, the prosthesis deployment and position in relation to aortic root were evaluated.
(8) Particularly, the distance between the lower rim of the prosthesis frame in the LVOT 
and the native aortic annulus at the level of the left coronary cusp (LCC) was measured 
(Figure 1). Moreover, the distance between the upper rim of the valve frame and the 
right and left coronary ostia was evaluated. Additionally the prosthesis deployment was 
visualized at the double-oblique transverse plane of the aortic annulus. At this level, the 
area of the deployed prosthetic valve was assessed by planimetry and additionally the 
maximal and minimal diameters of the prosthetic valve frame were measured.
Following previous studies, an eccentricity index, calculated as [1-(minimum prosthe-
sis diameter /maximum prosthesis diameter)] ≥0.1 defined a noncircular deployment of 
the prosthesis.(8) Moreover shallow or deep implantation of the frame were evaluated 
and defined as depth of the frame in the LVOT<2 mm or >8 mm from the level of the 
hinge point of the LCC, respectively (Figure 1).
Additionally the difference between the MDCT derived coronal and maximal diam-
eters of the aortic annulus and the nominal diameter of the implanted prosthesis were 
calculated. Furthermore, the difference between the MDCT derived aortic annular area 
and the nominal area of the implanted prosthesis was also assessed. Among several 
pre- and post-TAVI MDCT parameters, the determinants of PAVR were evaluated.
All analyses were performed with a package of SPSS software version 17, (SPSS Inc., 
Chicago, IL, USA). Based on visual inspection of the histograms and the Kolmogorov-
Smirnov tests, continuous variables were considered normally distributed and presented 
as mean and standard deviation or non-normally distributed and presented as median 
and interquartile range. Categorical variables are presented as number and frequencies. 
Patients were categorized according to the presence of non-significant PAVR (<2+) or 
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significant PAVR (≥2+) at 1-month follow-up. Continuous variables were compared with 
the unpaired Student’s t-test if normally distributed or the Mann-Whitney test other-
wise. Categorical variables were also compared with the χ2 test or Fisher’s exact test, as 
appropriate. Receiver operating characteristic curve analyses were performed to assess 
the accuracy of several MDCT parameters to predict the presence of PAVR≥2+ and the 
cut-offs values for each variable were obtained from the highest sum of sensitivity and 
specificity. Binary logistic regression analysis was performed to evaluate independent 
determinants of PAVR≥2+ and the estimated odds ratios (OR) and the 95% confidence 
intervals (CI) were calculated. Variables with a p<0.1 in the univariate analysis were 
included in the multivariate model. A two-sided p<0.05 was considered statistically 
significant.
Figure 1. Examples of optimal (6.7 mm), shallow (0 mm) and deep (10.9 mm) deployment of prosthesis in 
the left ventricular outflow tract, leading to trivial, mild and trivial paravalvular regurgitation at 1 month fol-
low up, respectively. Shallow deployment was considered <2 mm and deep deployment >8 mm distance 
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RESULTS
A total of 123 patients (81±7 years, 49% male) with symptomatic severe aortic stenosis 
treated with TAVI and complete evaluation including pre- and post-TAVI MDCT were 
evaluated. The baseline characteristics of the patients are listed in Table 1.
Repeated balloon-dilatation of the prosthesis was performed in 15 (12.2%) patients. 
In 10 (66%) patients PAVR significantly reduced (<2+) after this intervention. At 1-month 
follow-up, all patients underwent TTE. In 30(24.4%) patients, no PAVR was observed 
whereas in respective 68 (55.3%), 22 (17.9%) and 3 (2.4%) patients, trivial-to-mild, mild-
to-moderate and moderate-to-severe PAVR were documented. Therefore, significant 
PAVR≥2+ was observed in 25 (20.3%) patients. In 5 of these patients a repeat balloon 
dilatation was performed.
Table 1. Baseline characteristics of overall population and patients with and without significant paravalvu-










Age (years) 81±7 81±7 80±7 0.446
Men 60 (49%) 50(51%) 10 (40%) 0.325
Body surface area (m2) 1.7±0.3 1.7±0.3 1.7±0.4 0.998
Hypertension 47 (38%) 38 (39%) 9 (36%) 0.799
Diabetes melitus 36 (29%) 30 (30%) 6 (24%) 0.517
Peripheral vascular disease 23 (19%) 21 (21%) 2 (8%) 0.158
Smoking 28 (22%) 23 (23%) 5 (20%) 0.796
Coronary artery disease 87 (71%) 70 (71%) 17 (68%)  0.737
New York Heart Association 
functional class III-IV
75 (61%) 62 (63%) 13 (52%) 0.303
Pacemaker 12 (10%) 10 (10%) 2 (8%) 1.000






















Logistic EuroSCORE 23.4 ±14.1 23.4±14.3 21.6±13.6 0.567
Aortic valve area (cm2) 0.73±0.18 0.72±19 0.78±0.15 0.108
Mean transaortic valve 
gradient (mmHg)
42±15 42±15 39±13 0.421
Left ventricular end-systolic 
volume (ml)
60±40 60±40 62±39 0.771
Left ventricular end-diastolic 
volume (ml)
112±48 113±48 109±47 0.733
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Patients with PAVR<2+ and patients with PAVR≥2+ had comparable Agatston aortic 
valve scores and similar aortic valve annular diameters and area measured at pre-
procedural MDCT scans (Table 2). However, the difference between the aortic annulus 
diameter measured in the coronal plane and the nominal diameter of the implanted 
prosthesis was significantly larger in patients with PAVR≥2+, compared with patients 
without significant PAVR. Similarly, the difference between the maximum aortic annulus 
diameter measured at the double-oblique transverse cross-sectional plane and the 
nominal diameter of the implanted prosthesis was significantly larger in patients with 
PAVR≥2+ compared with patients without significant PAVR. In contrast, there were no 
significant differences between groups in terms of difference between aortic annular 
area and nominal frame area (Table 2).
Based on post-TAVI MDCT data, the percentage of eccentrically deployed valves was 
higher among patients with PAVR≥2+ compared with patients without significant PAVR, 
although this difference was not statistically significant. In terms of positioning of the 
transcatheter aortic valve, patients with PAVR≥2+ showed more often a shallow posi-
tioning of the frame in the LVOT (<2mm) compared to patients without significant PAVR. 
In contrast, a deep positioning of the frame (>8mm) in the LVOT was not significantly 
different between groups (Table 2).
At multivariate analysis, the difference between the MDCT derived maximum diam-
eter of the aortic annulus and the nominal diameter of the implanted prosthesis and 
depth of frame in LVOT <2mm were independently associated with PAVR≥2+ at 1 month 
follow-up (Table 3). Receiver operating characteristic curves were performed to evaluate 
the accuracy of MDCT measurements to predict the occurrence of PAVR≥2+ (Figure 2).
Interestingly, implanting a transcatheter aortic valve which nominal diameter was 
undersized ≥2 mm relative to the maximum aortic annulus diameter measured on pre-
procedural MDCT had 72% sensitivity and 61.2% specificity to predict PAVR≥2+ (Figure 2).
Table 1. Baseline characteristics of overall population and patients with and without significant paravalvu-










Left ventricular ejection 
fraction (%)
50±13 50±13 48±13 0.510
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Table 2. Pre- and post-procedural multidetector row computed tomography parameters in patients with 
and without significant paravalvular aortic regurgitation at follow up







Agatston aortic valve score 2612±1394 2666± 1222 0.862
Aortic annular dimensions
 Coronal diameter (mm) 25.4± 2.1 26.0 ± 2.5 0.271
 Sagittal diameter (mm) 22.8±2.0 22.6±2.2 0.551
 Maximum diameter (mm) 27.1±2.4 27.9±2.3 0.092
 Minimum diameter (mm) 21.1±2.0 21.2±1.9 0.868
 Planimetered area (cm2) 4.26±0.76 4.19±0.82 0.694
Difference between coronal diameter of the 
aortic annulus and the nominal diameter of the 
implanted prosthesis (mm)
0.03±1.8 1.23±1.8 0.004
Difference between maximum diameter of the 
aortic annulus and the nominal diameter of the 
implanted prosthesis (mm)
1.6±2.2 3.1±1.6 0.004
Difference between the aortic annulus area and 
the nominal frame area (cm2)
−0.83±0.69 −0.65±0.67 0.237
Prosthetic valve eccentricity ≥0.1 10 (10%) 6 (24%) 0.067
Depth of frame in the left ventricular outflow tract 
<2 mm
7 (7%) 7 (28%) 0.003
Depth of frame in the left ventricular outflow tract 
>8 mm
7 (7%) 3 (12%) 0.428
Table 3. Univariate and multivariate binary logistic regression analyses
Variable Univariate analysis Multivariable analysis
Odds ratio (95% 
confidence 
interval)




Agatston aortic valve score 1.000 (1.000-1.000) 0.860 …. ….
Aortic annular maximum diameter 1.177(0.973-1.424) 0.094 0.718(0.498-1.035) 0.076
Difference between maximum diameter 
of the aortic annulus and the nominal 
diameter of the implanted prosthesis
1.398(1.122-1.744) 0.003 1.912(1.257-2.908) 0.002
Prosthetic valve eccentricity ≥0.1 2.779(0.900-8.577) 0.075 2.724(0.690-10.761) 0.153
Depth of frame in the left ventricular 
outflow tract <2 mm
5.056(1.580-16.180) 0.006 4.865(1.331-17.786) 0.017
Depth of frame in the left ventricular 
outflow tract >8 mm
1.773(0.424-7.411) 0.433 …. ….
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dISCUSSION
The present study indicates that a large difference between the maximal annulus di-
ameter and the nominal diameter of the prosthesis, as well as a shallow position of the 
frame in the LVOT, are independently associated with significant PAVR after TAVI. MDCT 
is a valuable imaging technique to understand the underlying mechanisms of PAVR after 
TAVI.
Several studies have consistently shown that aortic annulus dimensions are strongly 
associated with PAVR after TAVI.(5-7)Therefore, accurate measurement of aortic annulus 
dimensions is crucial to select the most appropriate prosthesis size and optimize the 
outcomes of TAVI. Accumulating evidence shows that 3-dimensional imaging techniques 
such as MDCT are the most accurate methods to size the aortic valve annulus.(5-7) How-
ever, the golden standard measurement of the aortic annulus to select the most appro-
priate prosthesis size has not been established to date. Mean aortic annulus diameter 
Figure 2. Receiver operating characteristic curve analyses of multidetector row computed tomography 
- related measurements of the aortic annulus to predict the occurrence of significant postoperative para-
valvular aortic regurgitation.
Abbreviations: AUC= area under the curve; CI= confidence interval; Std. Error= standard error.
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(derived from the average of the minimum and maximum diameters), area-derived 
diameter, coronal and sagittal diameters have been proposed to select the transcatheter 
valve size.(5-7) Importantly, the nominal diameter of the available transcatheter valves 
should be taken into consideration to estimate the grade of over- or undersizing relative 
to the aortic annulus once the valve is implanted. A significant oversizing of the prosthe-
sis will minimize the risk of significant PAVR at the expense of increasing the potential 
risk of aortic annulus rupture whereas a significant prosthesis undersizing will increase 
the risk of significant PAVR and, less frequent, prosthesis migration. Jilaihawi et al dem-
onstrated that the difference between the maximum diameter of the aortic annulus as 
assessed with MDCT and the nominal diameter of the implanted prosthesis had the best 
accuracy to predict significant PAVR after TAVI.(6) Similarly, Willson et al showed that 
patients with a nominal transcatheter valve area <10% larger than the cross-sectional 
area of the native aortic annulus (less oversized) had significantly higher incidence of 
PAVR as compared to patients with a difference >10% (more oversized) (19.1% vs. 0%; 
odds ratio 18.4, p<0.01).(7) Furthermore, Hayashida and coworkers demonstrated that 
the use of MDCT to measure the aortic valve annulus resulted in lower incidence of PAVR 
after TAVI as compared with 2-dimensional transesophageal echocardiography. (5 )The 
ratio between the nominal diameter of the transcatheter valve and the mean diameter 
derived from the cross-sectional area of the aortic valve annulus measured with MDCT 
was strongly associated with the presence of significant PAVR after TAVI (hazard ratio 
0.36 per each 0.1 increase; 95% confidence interval 0.17-0.77). (5) In the present study the 
difference between the maximum diameter of the aortic annulus assessed with MDCT 
and the nominal diameter of the implanted prosthesis predicted best the presence of 
significant PAVR after TAVI. Therefore, estimation of the degree of prosthesis oversizing 
seems to be an important parameter to minimize the incidence of significant PAVR. 
However, this parameter should be further confirmed in prospective studies.
In addition, calcification of the aortic valve has been related to the presence of signifi-
cant PAVR.(19-21) However, it remains unclear the relative merits of the total amount of 
valve calcification or the (asymmetrical) location of calcification.(19, 20) In the present 
study, there were no differences in the amount of valve calcification (as quantified with 
the Agatston valve score) between the two groups of patients.
Few series have reported on the association between post-TAVI MDCT parameters, 
such as deployment and position of the transcatheter prosthesis and the presence of 
significant PAVR.(8, 22) Eccentricity of the deployed prosthesis and position into the LVOT 
(particularly depth) have been related with significant PAVR.(8, 23, 24) The prevalence of 
asymmetric deployed prosthesis is variable according to the different series (ranging 
between 2% for balloon-expandable prosthesis to 83% for self-expandable prosthesis).
(22, 25) In the present study the prevalence of eccentric deployed prosthesis was 10% 
and it was not independently associated with the presence of significant PAVR.
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Furthermore, the depth of the deployed valve in the LVOT as assessed with left ven-
triculography has been related to PAVR in patients treated with self-expandable pros-
theses.(24) Sherif et al demonstrated that the optimal position of the self-expandable 
prosthesis was approximately 10 mm deep into the LVOT (as measured from the an-
nular hinge point of the non-coronary cusp).(24) A depth >10 mm may leave part of the 
prosthesis frame uncovered by the sealing skirt into the LVOT and subsequently the 
blood may regurgitate through the frame struts. In contrast, a shallow position of the 
prosthesis may be associated with malapposition of the frame into the annulus that 
leads to subsequent PAVR. In the present evaluation a shallow position of the frame was 
significantly associated with the presence of significant PAVR at follow-up. These results 
therefore confirm previous studies underscoring the relevance of accurate positioning 
of the prosthesis frame.
Some limitations should be acknowledged. The grading of PAVR remains challeng-
ing and although echocardiography may be the first choice imaging technique to use, 
many centers still grade PAVR based on angiographic scores immediately at the hybrid 
room.(26) Although an integrative approach was used to grade PAVR (as advocated by 
current recommendations),(16, 27)some of the variables were not systematically feasible 
(such as for example diastolic flow reversal in the descending aorta). In addition, 24% 
of patients had atrial fibrillation which may impact on the echocardiographic measure-
ments. Furthermore, the present population included a majority of patients undergoing 
transapical TAVI. In addition, the present results are based on one commercially available 
transcatheter prosthesis (the Edwards Sapien and Sapien XT valves) and mainly on 23- 
and 26 mm valves. Therefore, the results may not be applicable to other manufacturers.
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background: New onset rhythm conduction disorders are frequent after transcatheter 
aortic valve implantation (TAVI). Multi-detector row computed tomography (MDCT) may 
help elucidate the pathophysiology of rhythm conduction disorders in patients treated 
with the Edwards SAPIEN valve. Methods: A total of 94 patients (age 81±7 years, men 
48%) treated with TAVI with the Edwards SAPIEN valve and undergoing a pre- and post-
TAVI MDCT were included. Patients with pre-existent right or left bundle branch block 
(LBBB) and permanent pacemakers were excluded. Position and deployment of the 
transcatheter frame into the aortic root was evaluated at post-TAVI MDCT. Pacemaker 
implantation or new onset LBBB at 1 month follow-up was the combined endpoint. 
Results: Overall, 1 pacemaker was implanted and 14 new onset LBBB were recorded. 
Among several tested clinical and MDCT variables, overexpansion of the transcatheter 
valve >15% of the native annulus area (odds ratio 5.277, 95% confidence interval 1.398-
19.919, p = 0.014) and depth of frame into the left ventricular outflow tract (LVOT) (odds 
ratio1.401, 95% confidence interval 1.066-1.770, p = 0.010) were independently related to 
the need for pacemaker or new onset LBBB. Conclusions: Overexpansion of the trans-
catheter prosthesis by >15% of native aortic annulus area and implantation depth of the 
frame into the LVOT are independently associated with the need for pacemaker or new 
onset LBBB in patients undergoing TAVI with the Edwards SAPIEN valve.
Multi-detector row computed tomography after transcatheter aortic valve implantation 37
INTROdUCTION
New onset persistent left bundle branch block (LBBB) after transcatheter aortic valve 
implantation (TAVI) has been described in 10-19% of patients receiving an Edwards 
SAPIEN prosthesis (Edwards Lifesciences, Irvine, CA) and in 28-57% of patients receiving 
a CoreValve system (Medtronic, Minneapolis, MN).(1-4) Likewise, the need for permanent 
pacemaker implantation is higher among recipients of the CoreValve system (23-33%) 
compared with recipients of the Edwards SAPIEN valve (2.5-11.5%).(3-6) Besides the dif-
ferent design characteristics of these two devices, which may be associated with the 
differences in incident new onset LBBB or pacemaker implantation, baseline QRS com-
plex duration and deep implantation of the prosthesis into the left ventricular outflow 
tract (LVOT) have been consistently associated with these complications after TAVI.(2,4) 
Particularly, the implantation depth may vary considerably with the CoreValve system 
which has a longer frame than the Edwards SAPIEN valve. The series that have observed 
the association between implantation depth into the LVOT and the development of new 
onset LBBB and need for permanent pacemaker have assessed this parameter based 
on aortograms performed immediately after valve deployment.(2,4) The higher spatial 
resolution of multi-detector row computed tomography (MDCT) allows more accurate 
evaluation of the spatial relationships of the implanted prosthesis into the aortic root 
and may help elucidate the pathophysiology of the development of new onset LBBB 
and need for permanent pacemaker in patients undergoing TAVI. The present study 




The study included 94 patients undergoing TAVI with the Edwards SAPIEN valve (Ed-
wards SAPIEN or SAPIEN XT, Edwards Lifesciences, Irivine, CA) at the Leiden University 
Medical Center (Leiden, The Netherlands). Information about inclusion criteria in the 
TAVI registry and procedural details has been previously described in detail.(7) Patients 
with bioprosthetic aortic valves and valve-in-valve implantation as a bailout procedure 
were excluded. Unless contraindicated, patients referred for TAVI are evaluated with 
pre-procedural MDCT for accurate measurement of the native aortic annulus and valve 
sizing. One month after TAVI, a second MDCT is performed in order to define the deploy-
ment of the prosthesis in the LVOT and aortic root. Following successful TAVI procedure 
patients are followed-up in the outpatient clinic with scheduled visits at 1, 3, 6 and 12 
months. Clinical evaluation, surface electrocardiogram (ECG) and echocardiography 
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are routinely performed. All clinical information on demographics, ECG, and imaging 
techniques are digitally stored in the departmental database (EPD vision version 8.3.3.6; 
Leiden, The Netherlands) and can be retrospectively analyzed. For this study, baseline 
clinical data in combination with pre- and post-TAVI MDCT parameters were related 
to the combined endpoint: need for pacemaker implantation or new onset persistent 
LBBB at 1 month follow-up. For this retrospective analysis, the Institutional Review Board 
waived the need for patient written informed consent.
ECg analysis
All ECGs were retrospectively reviewed at 3 time points: baseline (pre-TAVI), during hos-
pitalization and at 1 month follow-up. The presence of RBBB and LBBB was diagnosed 
according to current recommendations.(8) Duration of the PR interval and QRS complex 
were automatically calculated with dedicated software (Ziemens/ Dräger, Mega Care 
ECG Management System, Lubeck, Germany).
Multi-detector row computed tomography
A 64- or a 320-detector row computed tomography scanner was used for pre-operative 
and post-operative scanning of the patients. When the Aquilion 64 system (Toshiba 
Medical Systems, Otawara, Japan) was used, data were acquired with a collimation of 64 
x 0.5 mm and a gantry rotation time of 400 ms (tube current was 300-400 mA, voltage 
was 120 kV or 135 kV) and when the AcquilionONE system was used, data were acquired 
with a collimation of 320 x 0.5 mm (gantry rotation time of 350 ms, tube current and 
voltage set at 400-580 mA and 100 kV, 120 kV or 135 kV according to patients body mass 
index).
According to the acquisition protocol, patients with heart rate ≥70 beats per minute 
received beta-blockers unless contraindicated. A volume of 80-90 mL of non-ionic con-
trast (Iomeron 400, Bracco, Milan, Italy) was used according to patients’ body surface 
area. Scans were acquired in mid-inspiratory breath-hold and data was digitally stored.
Post-processing workstations (Vitrea2, Vital Images, Minneapolis, Minnesota, USA) 
were used for off-line analysis of the data. In the pre-TAVI MDCT data, the Agatston 
score of the aortic valve annulus and the LVOT was calculated. The calcification of LVOT 
(sub-annular landing zone) was semiquantitatively graded (1: none, 2: mild, 3: moder-
ate, 4: severe).(9) Accurate measurements of the aortic annulus and root dimensions 
were performed. Aligning the coronal, sagittal and transverse orthogonal planes across 
the aortic annulus, the cross sectional area, minimum and maximum diameters were 
measured.(10) In the post-TAVI MDCT, the expansion of the aortic valve was defined at 
the same level of the aortic annulus. Using the inner margins of the expanded frame 
as reference, the maximum and minimum diameters were measured and the effective 
area of expansion was planimetered. To define the depth of implantation, the distance 
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between the rim of the frame in the LVOT and the native aortic annulus was measured 
(Figure 1).(10)
The ratio (effective planimetered prosthesis area - MDCT derived aortic annulus 
area)/MDCT derived aortic annulus area was calculated from pre- and post-TAVI MDCT 
measurements as a parameter of prosthesis expansion. Prosthesis overexpansion was 
considered significant when the area of the expanded frame was >15% larger than the 
native aortic annulus valve area.(9,11)
Statistical analysis
A package of SPSS software version 20, (SPSS Inc., Chicago, IL, USA) was used for all 
statistical analyses. Continuous variables were considered normally or not normally 
distributed based on visual inspection of the histograms and were presented as mean 
and standard deviation or median and inter-quartile range, respectively. Categorical 
variables were presented as number and frequencies. Patients were categorized accord-
ing to the need for new pacemaker implantation or the induction of new onset LBBB 
(patients with combined endpoint vs. patients free of combined endpoint). Continuous 
variables were compared with the unpaired Student’s t-test if normally distributed or 
Figure 1. Multi-detector row computed tomography can define implantation depth of the frame in the 
left ventricular outflow tract. The red line illustrates the level of the native aortic annulus. The distance 
between the native aortic annulus and the lower rim of the frame in the left ventricular outflow tract can 
be measured. There was an induction of a new onset left bundle branch block in patients (A) and (B) at one 
month follow-up and a new pacemaker was implanted in patient (C) at the 5th postoperative day. LVOT: left 
ventricular outflow tract. TAVI: transcatheter aortic valve implantation.
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the Mann-Whitney test otherwise. Categorical variables were compared with the χ2 test 
or Fisher’s exact test, as indicated. Binary logistic regression analysis was used for the 
evaluation of the occurrence of the combined endpoint at 1 month follow-up and the 
estimated odds ratios and the 95% confidence intervals were calculated. Variables with a 
p < 0.1 in the univariable model were included in the multivariable analysis. A two-sided 
p < 0.05 was considered statistically significant.
RESULTS
Patient characteristics
From an initial cohort of 161 patients in whom a pre- and post-procedural MDCT was 
available, 21 patients with right bundle branch block (RBBB), 24 patients with LBBB and 
22 patients with permanent pacemakers at baseline were excluded. Baseline clinical and 
echocardiographic characteristics of the remaining 94 patients (81±7 years old, 48% 
men) who were finally included in the current analysis are outlined in Table 1. The mean 
logistic Euroscore was 20.0±11.7%. Fifty-six (60%) patients had NYHA II-IV heart failure 
symptoms. Overall, 38 (40%) patients were treated through a transfemoral approach 
and the remainder 56 (60%) through a transapical approach. The size of the implanted 
vales was 23 mm in 28 (30%) patients, 26 mm in 62 (66%) and 29 mm in 4 (4%). In 9 (10%) 
patients, reballooning of the implanted prosthesis was performed to minimize paraval-
vular aortic regurgitation. Eighty patients were in sinus rhythm and the remaining 14 
patients had atrial fibrillation. In patients in sinus rhythm, the PR interval was 179±24 ms. 
In the overall population, the mean QRS duration was 98±10 ms and 7 (7%) patients had 
left axis deviation.
Table 1. Baseline characteristics of patients
Clinical data n = 94
Age (years) 81±7
Male, n (%) 45(48)
Body surface area (m2) 1.71±0.31
Creatinine (μmol/L) 87(70-101)
Hypertension, n (%) 40(43)
Diabetes, n (%) 28(30)
Smoking, n (%) 22(23)
Coronary artery disease, n (%) 65(70)
CABG, n (%) 24(26)
NYHA functional class III-IV, n (%) 56(59)
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Conduction abnormalities
Compared to baseline ECG, there was a significant increase in QRS duration in the pre-
discharge ECG (from 98±10 ms to 112±22 ms, p < 0.000) but not in PR interval (from 179 
±29 ms to 180±41 ms, p = 0.878). At this time point, new onset left axis deviation in the 
ECG was observed in 7 (7%) patients and 11 (11%) patients developed new onset RBBB. 
New onset LBBB developed in 15 (16%) patients pre-discharge. Moreover, 1 (1%) patient 
Table 1. Baseline characteristics of patients (continued)





 Calcium channel blockers 29(31)
Logistic Euroscore (%) 20.0±11.7
Procedural data
Transfemoral, n (%) 38(40)
Transapical, n (%) 56(60)
Balloon post-dilatation, n (%) 9(10)
Edwards SAPIEN valve
 23 mm, n (%) 28(30)
 26 mm, n (%) 62(66)
 29 mm, n (%) 4(4)
Echocardiography data
Aortic valve area (cm/m2) 0.72±0.19
Intra-ventricular septum thickness (cm) 1.4±0.2
Mean transaortic gradient (mmHg) 43±17
Peak transaortic gradient (mmHg) 70±25
Left ventricular ejection fraction (%) 51±12
MdCT data
Agatston score of the aortic valve and LVOT (Hounsfield units) 2927±1643
LVOT ‘landing zone’ calcification (grade 1-4) 2(2-3)
baseline ECg data
Heart rate (beats/min) 72 ± 12
Atrial fibrillation, n (%) 14(15)
PR interval duration (ms) 179±24
QRS duration (ms) 98±10
Left axis deviation, n (%) 7(7)
ECG: electrocardiogram; CABG: coronary artery bypass grafting; LVOT: Left ventricular outflow track; MDCT: 
multidetector row computed tomography; NYHA: New York Heart Association
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underwent a dual-chamber pacemaker implantation 5 days after TAVI due to persistent 
3rd grade atrio-ventricular block (Figure 1).
Compared to pre-discharge ECG, there were no significant changes in QRS complex 
or PR interval duration at 1 month follow-up (from 112±22 ms to 111±23 ms, p = 0.461 and 
from 180±41 ms to 179 ±36 ms, p = 0.781, respectively). In the repeat surface ECG at 1 
month there were 7 (7%) patients with left axis deviation, 10 (10%) patients with RBBB 
and 14 (14%) patients with LBBB. New onset inhospital RBBB and LBBB resolved in 1 and 
2 patients at 1 month follow-up, respectively. Moreover 1 patient developed a new onset 
LBBB post-discharge at 1 month follow-up. Consequently, the combined endpoint of the 
study at 1 month follow-up was met in 15 (16%) patients.
Post- TAVI MdCT
Post-TAVI MDCT scans showed that the deployed prosthesis was overexpanded by >15% 
of the native annulus area in 18 (19%) patients. Interestingly, Edwards SAPIEN valves 
expanded to their nominal area in only 2 patients whereas in the majority of patients 
frames were underexpanded. In the post-TAVI scan the mean depth of the deployed 
frame in the LVOT was 4.2±2.4 mm.
MdCT parameters associated with need for permanent pacemaker 
implantation and new onset Lbbb
The study endpoint (need for permanent pacemaker implantation and/or new onset 
persistent LBBB) was observed in 15 (16%) patients. As shown in Table 2, the proportion 
of Edwards SAPIEN valves that were overexpanded by >15% of the native aortic annulus 
as assessed with MDCT was higher in patients who met the study endpoint compared to 
patients free of the combined endpoint (6 (40%) vs. 12 (15%), p = 0.025). Also the frame 
was implanted deeper in the LVOT of patients that required a new pacemaker or devel-
oped new LBBB compared to patients free of the combined endpoint (5.7±2.7 mm vs. 
4.0±2.3 mm, p = 0.014, respectively) (Table 2). Binary logistic regression analysis showed 
that overexpansion of the valve by >15% of the native aortic annulus (OR 5.277, 95% CI 
Table 2. Comparison between patients with new onset LBBB or need for pacemaker implantation at 1 







Age (years) 81±4 80±7 0.678
Male, n (%) 9(56) 37(47) 0.492
Body surface area (m2) 1.84±0.27 1.69±0.31 0.092
Creatinine (μmol/L) 83(57-97) 88(71-102) 0.556
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Table 2. Comparison between patients with new onset LBBB or need for pacemaker implantation at 1 







Hypertension, n (%) 9(60) 31(39) 0.136
Diabetes, n (%) 4(25) 24(30) 0.667
Smoking, n (%) 3(20) 19(24) 0.734
Coronary artery disease, n (%) 11(73) 54(68) 0.702
CABG, n (%) 5(31) 19(24) 0.648
NYHA functional class III-IV, n (%) 9(60) 47(59) 0.917
Medication
 Beta-blockers 8(47) 45(57) 0.609
 Diuretics 8(53) 47(59) 0.675
 Statins 10(40) 47(59) 0.602
 Calcium channel blockers 6(40) 23(29) 0.403
Logistic Euroscore (%) 22.7±9.4 19.4±12.1 0.332
Transfemoral, n (%) 6(38) 32(41) 0.832
Transapical, n (%) 9(60) 47(59) 0.971
Balloon post-dilatation, n (%) 2(13) 7(8) 0.865
Edwards SAPIEN valve
 23 mm, n (%) 2(13) 26(33) 0.129
 26 mm, n (%) 13(86) 49(62) 0.065
 29 mm, n (%) 0(0) 4(5) 0.373
Echocardiography data
Aortic valve area (cm/m2) 0.76±0.16 0.71±0.19 0.324
Intra-ventricular septum thickness (cm) 1.4±0.3 1.4±0.2 0.915
Mean transaortic gradient (mmHg) 45±21 43±16 0.634
Peak transaortic gradient (mmHg) 76±33 69±24 0.339
Left ventricular ejection fraction (%) 51±12 52±12 0.818
MdCT data
Agatston score of the aortic valve and LVOT 
(Hounsfield units)
3026±1765 2909±1633 0.814
LVOT ‘landing zone’ calcification (grade 1-4) 2(2-3) 2(2-3) 0.440
baseline ECg data
Heart rate (beats/min) 73±13 71±11 0.446
Atrial fibrillation, n (%) 3(19) 11(14) 0.629
PR interval duration (ms) 188±39 177±21 0.203
QRS duration (ms) 97±10 98±10 0.630
Left axis deviation, n (%) 7(46%) 0 (0%) 0.231
ECG: electrocardiogram; CABG: coronary artery bypass grafting; LVOT: Left ventricular outflow track; MDCT: 
multidetector row computed tomography; NYHA: New York Heart Association.
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1.398-19.917, p = 0.014) and depth of frame into the LVOT (OR 1.401, 95% CI 1.083-1.811, 
p = 0.010) were independently associated to the study endpoint (Table 3).
dISCUSSION
The present evaluation expands on the pathophysiological determinants of new onset 
persistent LBBB or need for pacemaker implantation in patients treated with TAVI using 
the balloon-expandable Edwards SAPIEN prosthesis. With the use of MDCT post-TAVI, the 
present evaluation demonstrated that overexpansion of the frame by >15% of the native 
annulus area and deep implantation of the prosthesis into the LVOT were independently 
related to the presence of new onset persistent LBBB and pacemaker implantation.
Table 3. Univariate and multivariate analysis of clinical, electrocardiogram and MDCT parameters related to 









Age (years) 1.018 (0.938-1.104) 0.675
Male, n (%) 1.297 (0.429-3.923) 0.645
Creatinine (μmol/L) 0.994 (0.976-1.013) 0.548
Diabetes, n (%) 0.833 (0.241-2.882) 0.833
CAGB, n (%) 1.447 (0.439-4.774) 0.544
NYHA functional class III-IV, n (%) 1.200 (0.364-3.957) 0.765
Beta-blockers, n (%) 0.795 (0.285-2.614) 0.863
Transfemoral, n (%) 0.979 (0.317-3.020) 0.971
Balloon post dilatation, n (%) 1.582 (0.295-8.480) 0.592
Aortic valve area (per cm/m2)  4.284 (0.241-76.231) 0.322
Intra-ventricular septum (per cm) 0.988 (0.797-1.225) 0.891
Left ventricular ejection fraction (%) 0.995 (0.953-1.038) 0.816
Agatston score (per 100 units) 0.999 (0.956-1.044) 0.959
LVOT ‘landing zone’ calcification 
(grade 1-4)
0.791 (0.437-1.430) 0.437
Overexpansion >15% of native 
annulus area, n (%)
 3.722 (1.119-12.382) 0.032 5.277 (1.398-19.919) 0.014
Depth of frame in LVOT (per mm) 1.320 (1.045-1.667) 0.020 1.401 (1.083-1.811) 0.010
Atrial fibrillation, n (%) 1.545 (0.375-6.371) 0.547
PR duration (per ms) 1.015 (0.992-1.040) 0.208
QRS duration (per ms) 0.987 (0.935-1.041) 0.626
ECG: electrocardiogram; CABG: coronary artery bypass grafting; LVOT: Left ventricular outflow tract; NYHA: 
New York Heart Association.
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Incidence of new onset Lbbb and need for pacemaker implantation after TAVI 
with the Edwards SAPIEN valve
The incidence of new conduction abnormalities in TAVI patients varies widely across 
the several trials.(1-3,12-22) Pre-existent conduction abnormalities, type of implanted 
prosthesis and timing and duration of new conduction abnormalities (early vs. late 
after TAVI2(2,5,17,18,23) and transitory versus persistent abnormalities(2,17,24)) are the 
main confounder factors underlying the disparate incidences. Few trials and registries 
have documented the incidence of new onset persistent conduction abnormalities and 
need for pacemaker implantation after TAVI in patients without preexistent conduction 
abnormalities.(1-3) The PARTNER trial and the continued access registry, including 1157 
patients without preexistent conduction abnormalities or pacemaker, reported an inci-
dence of new onset of LBBB of 10.5% before hospital discharge.(1) Urena et al reported 
an incidence of 30.2% in 202 patients undergoing TAVI with the Edwards SAPIEN valve.
(2) Using the self-expandable CoreValve system, Testa et al reported an incidence of new 
onset LBBB of 27.4%.(3) However, at mid follow-up, the prevalence of persistent LBBB 
reduced in all series: data from the PARTNER trials and the continued access registry 
showed a prevalence of persistent LBBB of 7.8% and 8.5% at 30 days and 6-12 months 
follow-up, respectively, whereas in the series by Urena et al LBBB resolved in 37.7% and 
57.3% of patients at hospital discharge and 6-12 months follow-up, respectively.(1,2) 
Among patients treated with the CoreValve system, Testa and colleagues reported no 
change in LBBB prevalence at 1 month follow-up.(3) The incidence of new onset persis-
tent LBBB in the present study (n = 14 patients, 15%) was comparable to previous studies 
including patients treated with the Edwards SAPIEN valve.
The incidence of new pacemaker implantation after TAVI has been reported in 9.2% 
to 42% among patients treated with a CoreValve system and in 2.5% to 11.5% in patients 
treated with the Edwards SAPIEN valve.(12,13,17-22,25) Preexistent RBBB or LBBB have been 
associated with increased risk of pacemaker implantation with complete atrioventricular 
block and symptomatic bradycardia being the main reasons for pacemaker implanta-
tion.(4,5,18,19) In the present study, patients with preexistent conduction abnormalities 
were excluded which would explain the low incidence of new pacemaker implantation. 
Complete atrioventricular block was the indication for pacemaker implantation.
MdCT associates of new onset Lbbb and need for pacemaker implantation 
after TAVI
Several clinical and electrophysiological parameters have been associated with in-
creased risk of new onset LBBB and pacemaker implantation after TAVI.(1-5,23,26) Among 
the several studies including patients with preexistent conduction abnormalities, Bagur 
et al(5) identified preexistent RBBB as predictor of pacemaker implantation in patients 
treated with the balloon-expandable valve. Among patients without preexistent con-
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duction abnormalities, data from the PARTNER trials and the continued access registry 
showed that prior coronary artery bypass grafting was associated with increased risk 
of new onset LBBB(1) while Urena et al demonstrated larger baseline QRS duration and 
deep implantation of balloon-expandable prosthesis into the LVOT as determinants of 
this endpoint.(2) A low implantation of the prosthesis frame into the LVOT was also iden-
tified by Testa and coworkers as determinant of persistent LBBB in patients treated with 
a self-expandable valve.(3) The implantation depth of the device has been assessed in 
previous studies with aortography performed during the TAVI procedure.(23) Few studies 
have evaluated with MDCT the position of the deployed frame into the LVOT and have 
correlated it with the occurrence of conduction disturbances.(24,27) Binder et al showed 
that the implantation depth of the Edwards SAPIEN frame was significantly lower into 
the LVOT in 4 patients developing new LBBB compared to patients without LBBB (5.5±2.9 
mm vs.3.4±2.9 mm).(24) Similarly, Caudron et al reported a mean implantation depth 
of 4.1± 2.6 mm in 7 patients who developed new conduction abnormalities post-TAVI 
compared to 2.0±2.4 mm in patients without new onset conduction disturbances.(27) 
The cardiac conduction system penetrates the membranous septum from right to left, 
and continues its course in the LVOT, giving rise to the left bundle branch which is at the 
base of a triangle defined by the right and non-coronary aortic cusps. A direct compres-
sion of the valve frame on the cardiac tissue in proximity to the conduction system may 
be the key factor to induce conduction disorders in TAVI patients.
Oversizing of the valve may also contribute to the compression force on the cardiac 
tissue adjacent to the conduction system, but the significance of this parameter has 
been debated.(2,4,23,24,26,28) Binder et al did not observe an association between over-
sizing or overexpansion of the frame and the occurrence of conduction abnormalities 
after TAVI, however only pre-discharge ECGs were evaluated and patients with baseline 
conduction disorders were not excluded.(24) The current study demonstrated that over-
expansion of the frame by >15% in relation to the native aortic annulus was related with 
new onset conduction abnormalities and that this association was independent from 
implantation depth. Calcification of the device landing zone in the LVOT and aortic root 
has been also proposed as an associate factor of need of pacemaker implantation.(29) 
In 67 patients without pacemaker prior to TAVI, using the CoreValve system, Latsios et 
al assessed semiquantitatively with pre-TAVI MDCT the amount of calcification into the 
device landing zone. In 32% of patients, a pacemaker was implanted prior to hospital 
discharge. The extent and amount of calcifications in the device landing zone were as-
sociated with increased risk of pacemaker implantation at follow-up (OR 1.06, 95% CI 
1.02-1.11, p = 0.004).(29) However, the present study does not confirm those results. The 
different transcatheter valves implanted and the definition of the endpoint may have 
precluded us to observe similar results.
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Limitations
Some limitations should be acknowledged. The study was retrospective and it was per-
formed in a single centre. Moreover, only Edwards SAPIEN and SAPIEN XT valves were 
used and results may not be reproducible with other commercially available valves.
CONCLUSIONS
Overexpansion of the Edwards SAPIEN frame by >15% of the native annulus area and low 
implantation in the LVOT were independently related to new onset of persistent LBBB 
and need for pacemaker implantation.
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Objectives: To determine the implications of stable coverage of the coronary ostia 
by the Edwards SAPIEN valve frame in terms of myocardial ischemia and subsequent 
percutaneous coronary intervention (PCI), following transcatheter aortic valve implan-
tation (TAVI). background: Edwards SAPIEN frame is frequently deployed relatively 
higher than recommended and may overlap the coronary ostia. Methods: A total of 
142 patients (age 81±7 years, male 49%) treated with Edwards SAPIEN valve and with 
multi-detector row computed tomography at 1 month follow-up were evaluated. The 
position of the frame in relation to the coronary ostia was assessed. Levels of troponin 
T were measured 12-24 hours after TAVI. PCI events at follow-up were recorded. Results: 
The left coronary ostium was fully covered in 3 (2.1%) patients and the right coronary 
ostium in 11 (7.7%). There were no differences in troponin T levels between patients with 
fully covered ostia vs. patients with partly or non-covered ostia (0.24 (0.13-0.50) μg/L vs. 
0.35 (0.15-0.55) μg/L, respectively; p = 0.377). At 30±15 months follow up, 10(7%) patients 
underwent successful PCI. Rate of subsequent PCI was similar between patients with 
any covered ostium and patients with non-covered ostia (4 (7.8%) vs. 6 (6.5%), p = 0.780, 
respectively). Conclusions: Full overlap of the coronary ostia by Edwards SAPIEN frame 
is infrequent and in most cases is not related with post-operative troponin T elevation 
and does not limit subsequent PCI.
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INTROdUCTION
Transcatheter aortic valve implantation (TAVI) is an alternative treatment for patients 
with severe aortic stenosis who are deemed non-operable or have a very high-risk 
for conventional cardiac surgery.(1,2) Accurate deployment of the device is crucial to 
avoid complications. Very low implantation of the device has been associated with 
paravalvular regurgitation, mitral valve dysfunction, conduction abnormalities, and less 
frequent with device migration into the left ventricle. (3,4) In contrast, high position of 
the device into the aortic root has also been associated with paravalvular regurgitation, 
coronary ostia obstruction and valve migration.(5,6) The recommended position of the 
Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA, USA), with 50% below and 50% 
above the native leaflet insertion, is not always achieved.(7) An asymmetrical, operator-
independent upward movement of the frame during the last steps of implantation may 
take place and lead to a higher final position of the device, reaching the coronary ostia.
(7) While acute occlusion of the coronary ostia is a very rare complication with a reported 
incidence between 0.6% and 1.1% (8,9), the prosthetic frame may reach and exceed the 
coronary ostia without limiting the blood flow in more than 10% of patients.(5,10,11) The 
implications of a stable coverage of the coronary ostia by the frame remain unexplored. 
The permeable struts of the frame permit normal blood flow through the coronary ostia 
and therefore, acute ischemic events may be avoided. However, at long term follow-up, 
the implications of this position for subsequent percutaneous coronary interventions 
(PCI) have not been described. Accordingly, the present evaluation aimed at reporting 
the prevalence of high position of the Edwards SAPIEN frame in relation to the coronary 
ostia and the clinical implications of stable coronary ostia coverage by the prosthetic 
frame in terms of post-procedural acute ischemic events and influence on the feasibility 
of PCI at long-term follow-up.
MATERIALS ANd METHOdS
Patients
From an ongoing registry of 261 patients undergoing TAVI in our center, a total of 142 
patients who underwent multi-detector row computed tomography (MDCT) after suc-
cessful TAVI with Edwards SAPIEN prostheses were evaluated. Demographic and clinical 
data, including symptoms, associated comorbidities and medication, were collected pri-
or to TAVI. According to the institutional protocol, patients underwent post-procedural 
MDCT evaluation of transcatheter valve position and deployment within the aortic root 
at 1 month follow-up, unless contraindications (renal dysfunction, uncontrolled atrial 
arrhythmias and contraindications for beta-blockers).(5)
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Based on post-operative MDCT images, the distance of the prosthetic frame in relation 
to the coronary ostia was measured and the prevalence of complete overlap between 
the prosthetic frame and the coronary ostia was assessed. In addition, the need of inva-
sive coronary angiography and PCI at long term follow up was recorded.
Clinical and imaging data were prospectively collected in the departmental Cardiol-
ogy Information System (EPD vision version 8.3.3.6; Leiden, The Netherlands) and retro-
spectively analyzed. The institutional review board approved the retrospective analysis 
of clinically acquired data and waived the need for written patient informed consent.
Echocardiography
The severity of aortic stenosis was confirmed with transthoracic echocardiography prior 
to TAVI. The aortic valve morphology (tricuspid/bicuspid) was assessed at the parasternal 
short-axis view and peak and mean transaortic gradients were measured in the apical 
long-axis view. (12) The aortic valve area was calculated with the continuity equation. (12) 
An aortic valve area <1.0 cm2 and/or a mean gradient ≥40 mmHg defined severe aortic 
stenosis. (13) Left ventricular (LV) end-diastolic and end-systolic volumes were measured 
according to the Simpson’s method and LV ejection fraction (LVEF) was derived. (12)
TAVI procedure
All patients underwent coronary angiography before the procedure and significant 
coronary artery lesions amenable to PCI were treated mainly with bare-metal stents. 
TAVI was performed under general anesthesia with fluoroscopy and transesophageal 
echocardiography guidance.(14,15) A transfemoral approach was performed in pa-
tients with appropriate ilio-femoral arterial tree anatomy as defined in pre-operative 
MDCT. Otherwise, TAVI was performed via a transapical approach. Aortic valve balloon 
dilatation was performed under rapid right ventricular pacing and subsequently, a 
23-, 26- or 29-mm Edwards SAPIEN or SAPIEN XT valve was implanted also under rapid 
right ventricular pacing. The results were evaluated with supra-aortic angiography and 
transesophageal echocardiography.
Assessment of myocardial injury after TAVI
Circulating levels of troponin T were measured at 6-hour intervals within 48 hours after 
TAVI. The peak release of troponin T was recorded. Myocardial injury was defined as 
troponin T circulating levels >0.5 μg/L (>10 times the 99th percentile of upper reference 
limit).(16)
Post-operative MdCT data acquisition and analysis
Post-operative MDCT scans were performed either with a 64-(Aquilion64, Toshiba 
Medical Systems, Otawara, Japan) or a 320-MDCT scanner (Toshiba Medical Systems, 
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Tochigi-ken, Japan). For the Acquilion 64 system (collimation 64 x 0.5 mm, rotation time 
of 400 ms, tube current 300-400 mA, voltage 120 kV or 135 kV depending on body mass 
index) an ECG-gated acquisition was performed and the reconstruction of data was 
made at 75-85% of cardiac cycle for diastole and 30-35% for systole. With the Acquilion 
ONE system (collimation 320 x 0.5 mm, rotation time 350 ms, tube current 400-580 mA, 
voltage 100 kV, 120 kV or 135 kV according to body mass index) the entire cycle could be 
scanned prospectively, applying maximal tube current at 75% (for heart rate <60 beats 
per minute) or 65-85% (for heart rate ≥60 beats per minute) of the RR interval. Data 
acquisition was obtained in mid-inspiratory breath-hold. A volume of 80-90 mL of non-
ionic contrast (Iomeron 400, Bracco, Milan, Italy) was administered, depending on renal 
function, scan time, and body weight. A heart rate <70 beats per minute was favored 
and achieved with beta-blockers if there was no contradiction. Post-processing analysis 
of MDCT images was performed on dedicated workstations (Vitrea2, Vital Images, Min-
neapolis, Minnesota, USA).
Using the 3 orthogonal multi-planar reconstruction planes, the spatial relation be-
tween the coronary ostia and the upper rim of the prosthetic frame was evaluated. The 
coronal plane was oriented to obtain a clear view of the left coronary ostium whereas 
Figure 1. A: From the coronal plane the image was oriented to a point where a clear view of the left main 
was obtained. At this level the depth of the frame in the left ostium was measured (3.2 mm). At the same 
time the axial distance of the frame from the left main could be assessed (5.5 mm). B: From the sagital plane 
a clear image of the right coronary artery was obtained. The depth of the frame in the right coronary artery 
(6.2 mm) was measured and also the axial distance of the frame from the right coronary artery (6.5 mm) 
could be assessed.
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the right coronary ostium was visualized in a sagittal view. In the coronal plane, the 
distance from the upper rim of the frame to the left coronary ostium was measured in all 
cases where the frame was reaching or exceeding the ostium (Figure 1A). In addition, the 
axial distance between the frame and the left ostium was measured in all cases where 
the frame was covering the ostium (Figure 1A). Similarly, the distance from the upper rim 
of the frame to the right coronary ostium was measured in the sagittal plane and the 
axial distance was assessed for frames exceeding the right coronary ostium (Figure 1B).
Follow-up
The occurrence of PCI after TAVI was analyzed retrospectively. The clinical indication for 
each procedure was defined. Specifically, all cases where PCI was performed through an 
ostium that was partly or fully covered were recorded.
Statistical analysis
A package of SPSS software version 20, (SPSS Inc., Chicago, IL, USA) was used for statisti-
cal analyses. Continuous variables were presented as mean and standard deviation if 
normally distributed or as median and interquartile range otherwise. Categorical vari-
ables were presented as number and frequencies. Patients were categorized according 
to the position of the prosthetic frame in relation to the coronary ostia (frame exceeding 
the ostia or not). Continuous variables were compared with the unpaired Student’s 
t-test if they were normally distributed or with the Mann-Whitney test otherwise. A p-
value<0.05 was considered statistically significant.
RESULTS
In the overall population of 261 patients, there were 2 (0.7%) acute coronary artery 
fatal occlusions: one patient undergoing transcatheter valve-in-valve implantation in a 
degenerated 25-mm Freestyle bioprosthesis (Medtronic, MN) in whom the degenerated 
prosthetic leaflets occluded the left main coronary ostia and one patient undergoing 
TAVI in a native valve in whom the native calcified leaflet occluded a low coronary os-
tium (11.2 mm from the aortic annulus). Among 142 patients (age 81±7 years, male 49%) 
with available post-TAVI MDCT, there were no cases of acute coronary ostia occlusion. 
Table 1 summarizes the clinical and echocardiographic characteristics of this population.
The mean logistic EuroSCORE was 22.8±13.8%. In 51(36%) patients, the transfemoral 
approach was feasible whereas in the remaining 91 (64%) patients, TAVI was performed 
through the transapical approach. A 23-mm valve was implanted in 38 (27%) patients, 
a 26-mm valve in 99 (70%) and a 29-mm valve in 5 (3%) patient. Six (4%) patients with 
degenerated aortic valve xenografts underwent valve-in-valve TAVI procedures. Moder-
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ate to severe aortic regurgitation was treated with re-ballooning in 15 (11%) patients and 
in 1 patient a valve-in-valve bailout procedure was necessary.
Prevalence of coronary ostia covering by the transcatheter prosthetic frame
The frame exceeded by 1 mm the caudal rim of the left coronary ostium in 48(33.6%) 
patients and the right coronary ostium in 60(42.3%).The left coronary ostium was fully 
covered in 3 (2.1%) patients and the right coronary ostium was fully covered in 11 (7.7%) 
patients. In 3 (2.1%) patients, the frame was covering both ostia (Table 2).
Frames that were fully covering the coronary ostia had a mean axial distance of 3.9 
(2.5-6.5) mm from the coronary ostia. Similarly, prostheses with incomplete overlap of 
the coronary ostia had an axial distance 3.9 mm (0-8) mm to the ostia. Table 3 sum-
marizes the characteristics of patients with full overlap between the transcatheter valve 
and the coronary ostia.
Table 1. Baseline characteristics of patients
N = 142
Age (years) 81±7
Male, n (%) 70 (49%)
Creatinine (µmol/L) 99±57
Hypertension, n (%) 55 (39%)
Hypercholesterolemia, n (%) 63 (44%)
Diabetes, n (%) 41 (29%)
Peripheral vascular disease, n (%) 31 (22%)
Smoking, n (%) 35 (25%)
Coronary artery disease, n (%) 99 (70%)
Logistic EuroSCORE 22.8±13.8
NYHA functional class III-IV, n (%) 83 (58%)
Pacemaker, n (%) 13 (9%)








 ACE-inhibitors / ARB-II 81 (57%)
Transfemoral / Transapical TAVI, n (%) 51 (36%) / 91 (64%)
Edwards SAPIEN XT valve 57 (40%)
Aortic valve area (cm2) 0.7±0.2
Mean transaortic gradient (mmHg)
Max transaortic gradient (mmHg)




ACE, Angiotensin converting enzyme; ARB II, angiotensin II receptor blocker; NYHA, New York Heart 
Association; TAVI: transcatheter aortic valve implantation
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Acute troponin T release
The median peak troponin T value after TAVI was 0.35 (0.15-0.55) μg/L. Overall 40 (28.1%) 
patients had post-operative myocardial injury (troponin T > 0.5 μg/L). There was no sig-
nificant difference in post-operative troponin T levels between patients with full overlap 
between the transcatheter valve frame and the coronary ostia and patients with partly 
overlapped or non-covered coronary ostia (0.24 (0.13-0.50) μg/L vs. 0.35 (0.15-0.55) μg/L, 
respectively; p = 0.377). Also there was no difference in post-operative troponin T release 
for patients with any ostia covered >3 mm by the frame vs. non covered or covered by ≤3 
mm (0.35 (0.15-0.62) μg/L vs. 0.35 (0.15-0.54) μg/L, p = 0.876). Patients with >3 mm but not 
fully overlapped ostia and patients with no overlapped ostia had comparable troponin 
T levels (0.35 (0.16-0.64) μg/L vs. 0.35 (0.14 vs. 0.45) μg/L, p = 0.965 respectively).Of note, 
troponin T elevation was significantly higher in patients treated through transapical 
as compared with transfemoral approach (0.54 (0.31-0.65) μg/L vs. 0.11 (0.05-0.18) μg/L, 
p < 0.000, respectively). There were no differences in troponin T levels between patients 
Table 2. Relation of the prosthetic frame with coronary ostia
Left coronary ostium Right coronary ostium both coronary ostia Any coronary ostia
>1 mm overlap 48 (33.6%) 60 (42.3%) 36 (25.4%) 72 (50.7%)
>3 mm overlap 31 (21.8%) 42 (29.6%) 22 (15.5%) 51 (35.9%)
Full overlap 3 (2.1%) 11 (7.7%) 3 (2.1%) 11 (7.7%)
Table 3. MDCT data of patients in whom the device frame fully overlapped the left or right coronary ostia. 






















1 Right 15.60 16.80 26 TF 0.02 - -
2 Right 16.40 16.20 26 TA 0.35 - -
3 Right 17.90 18.80 26 TA 0.24 - -
4 Right 20.40 17.00 23 TA 0.38 - -
5 Right 18.90 20.20 26 TF 0.04 - -
6 Right 18.30 18.10 26 TA 0.77 - -
7 Right 17.70 16.90 26 TF 0.13 - -
8 Right 16.80 16.30 26 TA 0.50 - -
9 Both 15.00 15.90 26 TA 0.51 T wave 
inversion I, aVL
-
10 Both 17.5 18 26 TA 0.22 T wave 
inversion I, V6
-
11 Both 16.50 16.40 26 TF 0.15 - LAD,RCA
Data are expressed as number, ECG, electrocardiogram; LAD, left anterior descending artery; LCO, left coro-
nary ostium; MDCT, multi-detector row computed tomography; PCI, percutaneous coronary intervention; 
RCA, right coronary artery; RCO, right coronary ostium; TA, transapical; TF, transfemoral
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with creatinine >90 µmol compared to those with ≤90 µmol/L (0.45 (0.14-0.62) μg/L vs. 
0.39 (0.15-0.51) μg/L, p = 0.154, respectively).
Percutaneous coronary intervention at follow-up
During a mean follow up of 30±15 months, 10 (7%) patients underwent PCI. The reason 
for intervention was angina in 7 (4.9%) patients, progressive dyspnoea in 2 (1.4%) pa-
tients and acute coronary syndrome in 1 patient (0.7%). The median time to PCI was 13 
(8-18) months. Of note, the rate of new PCI did not differ in patients full overlap between 
the frame and the coronary ostia and patients with partly overlapped or non-covered 
coronary ostia (1 (10%) vs. 9 (6%), p = 0.566, respectively) and patients with any ostium 
covered by >3 mm vs. patients with non-covered or covered by ≤3 mm ostia (4 (7.8%) 
vs. 6 (6.5%), p = 0.780, respectively).The rate of new PCI was also similar in patients with 
>3 mm but not fully overlapped ostia compared to patients with no overlapped ostia (3 
(7.5%) vs.6 (6.5%), p = 0.556 respectively). Overall 13 drug-eluting and 1 bare-metal stents 
were implanted in the left anterior descending artery (7 patients), right coronary artery 
(3 patients) and vein grafts anastomosed to the circumflex coronary artery (4 patients). 
Four PCIs were performed though a partly covered or fully covered coronary ostium. 
Specifically, one patient underwent PCI in a fully covered left ostium (axial plane distance 
3.9 mm) and a fully covered right coronary ostium (axial plane distance 5.7 mm) (Table 
3) (Figure 2A, B). In the two remaining patients, PCI was performed through a coronary 
ostium which was partly covered by 6 mm (axial plane distance 4.6 mm) (Figure 2C) and 
through a left coronary ostium impeded by 4.2 mm (axial distance 3.6 mm) (Figure 2D), 
respectively. All procedures were successful and without major complications.
Figure 2. Percutaneous coronary interventions in ostia that are covered by the valve frame. A. Left ostium 
fully covered by 8 mm (axial plane distance 3.9 mm).B. Right ostium fully covered by 8.5 mm (axial plane 
distance 5.7 mm) in the same patient. C. Left ostium covered by 6 mm (axial plane distance 4.6 mm). D. Left 
ostium covered by 4.2 mm (axial plane distance 3.6 mm).
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dISCUSSION
The present evaluation demonstrates that the frame of current balloon expandable 
valves (Edwards SAPIEN and SAPIEN XT) is frequently positioned below the coronary os-
tia and seldom exceeds their height. A position of the frame exceeding the coronary ostia 
did not increase the incidence of acute myocardial injury, neither did it hamper late PCI.
Position of the balloon-expandable prosthesis during TAVI
Accurate positioning of the transcatheter aortic valve into the aortic root is crucial to 
ensure proper function of the valve and minimize several complications such as device 
migration, paravalvular regurgitation or coronary ostia occlusion. The latter can occur 
during device deployment when a relatively long or bulky calcified native aortic cusp is 
pushed towards the coronary ostia or due to inappropriate high position of the device 
and the sealing cuff, for example.(17,19) This uncommon complication occurs immedi-
ately after device deployment and early diagnosis is essential for prompt and successful 
treatment.(19) However, a position of the balloon-expandable valve overlapping the 
coronary ostia without major clinical implications has been more frequently described.
(5,10,11) Manufacturer’s recommendations propose a 50% above and 50% below the 
aortic valve annulus as the ideal position for Edwards SAPIEN and SAPIEN XT valves. 
However, this position is not frequently achieved. In the evaluation of TAVI results with 
MDCT, Caudron et al demonstrated that the balloon-expandable prosthesis overlapped 
the left coronary ostium in 22 (71%) patients whereas the right coronary ostium was 
rarely covered by the device (9 [29%]).(11) The mean overlap between device and left 
and right coronary ostia were 2.5±2.7 mm and −0.7±3.5 mm, respectively. Fatal coronary 
occlusion was not described in any patient. However, the number of patients in whom 
the device completely exceeded the coronary ostia was not reported. Furthermore, 
Tamborini et al using 3-dimensional transthoracic echocardiography reported that in 16 
of 110 (14.5%) patients undergoing TAVI with balloon-expandable prosthesis, the upper 
rim of the device reached or exceeded the left coronary ostium.(10) In these patients, 
the left coronary ostium height ranged between 9.3 mm and 15.6 mm. In our series, 11 of 
142 (7.7%) patients showed full overlap between the prosthesis frame and the coronary 
ostia (Table 3). In the current study, the distance between the aortic annulus and the top 
wall of the left coronary ostium was 19.2 ± 2.6 mm and the right coronary ostium 19.8± 
2.8 mm respectively. In another recent study Dvir and co-workers reported the final 
position of the SAPIEN Edwards and SAPIEN XT valves in 68 patients undergoing TAVI 
(7). In the majority of the patients (91.2%) the final position of the prosthesis frame was 
higher than recommended and <40% of the device height was placed below the aortic 
valve annulus. During rapid pacing, an operator-independent upward movement of the 
device toward the aorta was reported resulting in a higher positioning of the frame.(7) 
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Interestingly, the described upward movement was asymmetrical with the lower part 
of the device showing a larger upward displacement than the upper part of the frame 
(3.2±1.4 mm vs. 0.75±1.5 mm, respectively) and resulting in a shortening of the frame. The 
relatively stable position of the upper part of the frame may reduce the risk of coronary 
ostia occlusion. The authors however, did not describe the position of the prosthesis 
frame in relation to the coronary ostia. The current study is the first to evaluate system-
atically and in detail the coverage of the ostia by the valve frame with MDCT in a large 
population of patients undergoing TAVI. The inclusion of a larger number of patients in 
combination with higher spatial resolution of MDCT may account for discrepancies with 
previous studies.(5,10,11) The higher rate of transapical TAVI implantation in our study 
may be attributed to routine use of preoperative MDCT for the definition of iliofemoral 
artery anomalies (tortuosity, calcification) which precluded transfemoral access.
Implications of full overlap between the device and coronary artery ostia
So far there have been reports of catastrophic events following occlusion of the coro-
nary ostia after TAVI.(8,9,18,19) However until now, the induction of paucisymptomatic 
ischemia has not been investigated. In our series, full overlap or covering of the ostia by 
>3 mm by the frame was not associated with higher risk of acute myocardial ischemia or 
release of post-operative troponin T compared with patients without significant overlap. 
The blood flow through the permeable struts of the frame may be satisfactory in most 
cases. Elderly patients undergoing TAVI have increased prevalence of coronary artery dis-
ease which may affect long-term mortality.(21) Although a strategy of preoperative PCI 
for significant coronary lesions was adopted, patients experienced late acute coronary 
events, angina and dyspnoea. Interestingly, in our series 7% of patients underwent PCI 
at 2 years follow up. So far, in most reported cases with acute occlusion of the coronary 
ostia during TAVI, an immediate PCI was feasible through the struts of the frame.(9,18,19) 
The current study confirms that late PCI through covered ostia is also feasible.
Limitations
Some limitations should be acknowledged. Only patients treated with Edwards SAPIEN 
valve were included and the percentage of transapical TAVI is relatively higher than 
other series. Moreover, the number of patients with covered ostia that underwent late 
PCI is small. In addition, functional tests to evaluate the presence of inducible myocar-
dial ischemia were not systematically performed at follow-up. This is a single center 
experience, and the results may not be generalized to other centers with higher rates of 
transfemoral access or different implantation techniques. Furthermore, the low number 
of acute fatal occlusions of the coronary ostia precluded us to investigate predictors of 
this complication. However, a low take-off of the left main coronary ostia observed in 
one patient is one of the risk factors described by previous studies. (20)
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CONCLUSIONS
Deployment of Edwards SAPIEN valve above the level of coronary ostia is not frequent 
and a full overlap of the ostia by the Edwards SAPIEN frame is unusual. This relative high 
position of the transcatheter valve frame is not associated with increased risk of acute 
myocardial ischemia. In addition, at long-term follow-up, PCI procedures after TAVI are 
feasible, even for cases where the Edwards SAPIEN valve frame is covering the ostia.
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background: Although pericardial effusion (PE) early after transcatheter aortic valve 
implantation (TAVI) has been reported in few registries, late PE at follow-up remains 
unexplored. Particularly, after transapical TAVI, diagnosis of PE with transthoracic echo-
cardiography (TTE) may be challenging. The present evaluation assessed the incidence 
of PE early after TAVI and at 1 month follow-up using TTE and multi-detector computed 
tomography (MDCT). The agreement between TTE and MDCT to diagnose the presence 
and severity of PE at 1 month follow-up was evaluated. Methods: Overall 293 patients 
undergoing TAVI were included. Pre-discharge TTE was performed in all patients. At 1 
month, repeat TTE was performed in 234 patients and additional MDCT evaluation in 
143 patients. Results: Pre-discharge small and moderate PE was observed in 74.1% and 
4.1% of patients, respectively, whereas significant PE was diagnosed in 8 (2.7%) patients 
without differences between procedural access: 1.6% vs. 3.6% for transfemoral and 
transapical respectively, p = 0.474. At 1 month new-onset moderate PE was noted in 6 
(2.5%) patients all of who underwent transapical TAVI. MDCT and TTE disagreed on the 
grade of PE in 38 patients. Importantly, 1 patient with small PE on TTE was considered 
having moderate PE and 2 patients with small and moderate PE were considered having 
large PE. Also, 2 patients with moderate PE on echocardiography were considered small 
PE on MDCT.Conclusions: Significant PE early after TAVI is infrequent. The prevalence of 
small and moderate PE remains stable at 1 month follow-up. MDCT refines the diagnosis 
of significant PE.
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INTROdUCTION
The incidence of clinically significant pericardial effusion (PE) following cardiac surgery 
ranges between 1-29%.(1-3) This wide variability may be related to the study design 
(prospective series including patients referred for pericardiocentesis versus retrospec-
tive unselected series), different definitions of clinically relevant PE (from moderate PE 
to cardiac tamponade) and timing and methodology of diagnosis (early after surgery 
[<7 days] or late [≥7 days]). The factors associated with early and late PE are different: 
while anticoagulation exceeding therapeutic levels is associated with early PE, post-
pericardiotomy syndrome is the main cause of late PE.(2,3) Transcatheter aortic valve 
implantation (TAVI) is a safe and feasible alternative for patients with symptomatic se-
vere aortic stenosis and high operative risk or contraindications for surgery. Data on the 
incidence of significant PE and cardiac tamponade among patients undergoing TAVI are 
scarce: Lange et al(4) reported an incidence of 13% while in the Pilot European Sentinel 
TAVI registry, cardiac tamponade was observed in 2.4% of patients and the incidence 
was significantly higher among patients undergoing non-transfemoral TAVI compared 
to transfemoral TAVI (3.8% versus 2.7%, respectively, p = 0.001).(5) However, it remains 
unknown whether significant PE may develop late at follow-up. In addition, in patients 
undergoing transapical TAVI, echocardiographic diagnosis of significant PE may be chal-
lenging.
Multi-detector row computed tomography (MDCT) provides better spatial resolution 
than echocardiography for the diagnosis of early and late complications of TAVI, includ-
ing significant PE. Although MDCT does not currently provide information on hemody-
namics to evaluate the presence of cardiac tamponade, it may provide a more accurate 
quantification and localization of the PE and indirect signs of tamponade.(6-8) The aim 
of the current study was to evaluate the incidence and prevalence of PE as assessed 
with echocardiography early (in-hospital) and late (1 month) after TAVI. The agreement 
between MDCT and echocardiography for the detection of PE at 1 month follow-up after 
TAVI was also evaluated.
METHOdS
From an ongoing registry of patients with symptomatic severe aortic stenosis under-
going TAVI at the Leiden University Medical Center, 293 patients with uneventful TAVI 
and with pre-discharge echocardiographic follow-up were included. After successful 
TAVI, clinical and echocardiographic follow-up were routinely performed at 1, 3, 6 and 
12 months. According to the institutional protocol, at 1 month follow-up a repeat MDCT 
was performed unless contraindicated, to evaluate the position of the expanded pros-
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thesis in the native aortic valve.(9) Demographic, clinical, echocardiography and MDCT 
information were digitally stored (EPD vision version 8.3.3.6; Leiden, The Netherlands) 
and were retrospectively analysed. Presence and severity of PE was assessed with echo-
cardiography before hospital discharge and at 1 month follow-up. In addition, among 
patients with 1-month echocardiography and MDCT follow-up, the agreement between 
these two imaging techniques to diagnose PE was assessed. The institutional review 
board approved the study and waived the need for patient written informed consent for 
retrospective analysis of clinically acquired data.
TAVI procedure
Transcatheter aortic valve implantation procedures were performed in the hybrid room 
under general anaesthesia and were guided by fluoroscopy and transesophageal echo-
cardiography (iE33, Philips Medical System, Andover, MA, USA). The CoreValve system 
(Medtronic Inc., Minneapolis, MN) was implanted using a transfemoral access while the 
Edward SAPIEN prostheses (Edwards Lifesciences, Inc., Irvine, CA) were implanted via 
a transfemoral access or a transapical access. Implantation technique for each device 
has been previously described.(10,11) Immediately after prosthesis deployment, the 
valve hemodynamics and presence of paravalvular regurgitation were assessed with 
transesophageal echocardiography. The presence of PE was also evaluated at the end 
of the procedure.
Echocardiography
Transthoracic echocardiography was performed with commercially available ultra-
sound systems (Vivid 7, E9, and S6, General Electric, Horten, Norway) equipped with 
M5S and M4S phased array probes. Cardiac chamber quantification was performed as 
recommended.(12) Left ventricular (LV) end-diastolic and LV end-systolic volumes were 
calculated using the Simpson’s method and LV ejection fraction was derived.(12) The 
morphology of the aortic valve (bicuspid or tricuspid) was examined at the parasternal 
short-axis view. Peak and mean gradients of the aortic valve were measured at the apical 
long-axis or 5-chamber views. The LV outflow tract diameter was measured in a zoomed 
view of the parasternal long-axis view. The aortic valve area (AVA) was derived with the 
continuity equation. The presence of PE was assessed following current recommenda-
tions.(8) From M-mode recordings of the parasternal long-axis view, the presence of a 
free-echo space between the epicardium and the parietal pericardium in systole and 
diastole indicates >50 mL effusion. An end-diastolic space between the epicardium and 
the parietal pericardium of <10 mm, between 10-19 mm and ≥20 mm defined small, 
moderate and large PE, respectively.(13) In addition, the location and distribution of the 
PE was also assessed from 2-dimensional data. Furthermore, the presence of chamber 
collapse during diastole on 2-dimensional echocardiography, >30% respiratory flow 
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variation of the transmitral E-wave on pulsed wave Doppler recordings together with 
inferior vena cava dilatation or blunting or reversal of diastolic hepatic vein flow during 
expiration, were echocardiographic criteria of cardiac tamponade.(8)
Multi-detector row computed tomography
MDCT data were acquired with two scanners: an Aquilion 64 system (Toshiba Medical 
Systems, Otawara, Japan) and an AcquilionONE 320-detector system. For the Aquilion 64 
system a collimation of 64 x 0.5 mm and a gantry rotation time of 400 ms were set. Tube 
current was 300-400 mA and voltage was 120 kV or 135 kV. The Acquilion ONE system 
used a collimation of 320 x 0.5 mm (gantry rotation time of 350 ms, tube current and 
voltage set at 400-580 mA and 100 kV, 120 kV or 135). Beta-blockers were administered 
to patients with heart rate ≥70 beats per minute, unless contraindicated. Non-ionic 
contrast (Iomeron 400, Bracco, Milan, Italy) was administered through the antecubital 
vein at a volume of 80-90 mL depending on the patient’s body surface area. Data were 
digitally stored and analyzed with dedicated software (Vitrea2, Vital Images, Minneapo-
lis, Minnesota, USA).
The presence of PE was assessed at 1 month follow-up, as previously described.(7) 
From the axial plane, the 4-chamber view was reconstructed and the largest diameter 
of the pericardial space in front of the right ventricle was measured. In the same plane, 
the largest diameter of the pericardium in the mid posterior wall of the LV was defined 
(Figure 1). The superior aortic recess plane - representing the pericardial cavity anterior 
to the aorta and the pulmonary artery- could not be reconstructed for all patients and 
was not systematically evaluated. Similarly to the echocardiographic classification, PE 
was considered small, moderate or large if any of the anterior, posterior and apical wall 
pericardial space was 1-10 mm, 11-19 mm or≥20 mm, respectively.
Statistical analysis
Statistical analyses were performed with a package of SPSS software version 20, (SPSS 
Inc., Chicago, IL, USA). Continuous variables were defined as normally or non-normally 
distributed according to visual inspection of the histograms, and were presented as 
mean and standard deviation or as median and inter-quartile range, respectively. The 
categorical variables were presented as number and frequencies. Categorical variables 
were compared with the χ2 test or Fisher’s exact test, as appropriate and p values <0.05 
were considered statistically significant.
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RESULTS
A total of 293 patients (80±7 years old, 50% male) who underwent TAVI were included. 
Edwards SAPIEN prostheses were implanted in 260 patients (73 of 23-mm, 166 of 26-mm 
and 21 of 29-mm size) and CoreValve prostheses were implanted in 33 patients (1 of 
23-mm, 7 of 26-mm, 24 of 29-mm and 1 of 31-mm size). Baseline characteristics of the 
population are outlined in Table 1.
Figure 1. Transthoracic echocardiography vs. MDCT to grade PE. Panel A1 shows the para-sternal long-axis 
view of the left ventricle and the presence of 1.3 cm space anteriorly to the right ventricle during the entire 
cardiac cycle which was interpreted as moderate PE. In contrast, MDCT did not confirm the diagnosis and 
showed the presence of pericardial fat around the right ventricle (panel A2). Panel B1 shows the paraster-
nal long-axis view of the left ventricle and the presence of 1.2 cm space posterior to the LV. On MDCT, the 
amount of PE was larger (2.2 cm) confirming the diagnosis of significant PE (panel B2). However, the echo-
cardiography of the patient did not show any sign of cardiac tamponade.
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Pre-discharge echocardiography was performed after a median of 2 days (interquar-
tile range: 1-3) after TAVI. Pre-discharge small, moderate and large PE was diagnosed 
in respective 217 (74.1%), 12 (4.1%) and 8 (2.7%) patients. Eight patients with clinical or 
echocardiographic signs of cardiac tamponade underwent pericardiocentesis. Rates 
of significant PE were slightly higher in patients treated through a transapical access 
compared with patients treated through a transfemoral access (6/168 (3.6%) vs. 2/125 
(1.6%), respectively p = 0.474).
After a median follow-up of 38 days (interquartile range 31-45), 234 patients underwent 
repeat echocardiography. Small and moderate PE was observed in 175 (74.8%) and 8 
(3.4%) patients, respectively. Severe PE was not observed in any patient. Interestingly 6 
(2.5%) patients, all of them treated with transapical TAVI, who did not show any PE or had 
Table 1. Baseline characteristics
N = 293
Age (years) 80±7
Male n (%) 148 (50%)
BSA (m2) 1.81±0.28
Creatinine (µmol/L) 88 (73-115)
Diabetes, n (%) 84 (28%)
Atrial fibrillation, n (%) 60 (21%)
Coronary artery disease, n (%) 186 (64%)
NYHA functional class III-IV, n (%) 166 (57%)
Logistic Euroscore (%) 22.3±14.0
Transfemoral n (%) 125(43%)
Transapical n(%) 168 (57%)
CoreValve n(%) 33 (11%)
Edwards SAPIEN n(%) 260 (89%)
Medication











Aortic valve area (cm2) 0.74±0.25
Mean transaortic gradient (mmHg) 43±18
Peak transaortic gradient (mmHg) 65±27
Left ventricular ejection fraction (%) 52±14
Left ventricular end diastolic volume (ml) 106±48
Left ventricular end systolic volume (ml) 55±40
ACE, Angiotensin converting enzyme; ARB-II, Angiotensin II receptor blocker; BSA, Body surface area; NYHA, 
New York Heart Association
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only small PE at pre-discharge echocardiography, were diagnosed with new onset mod-
erate PE at 1-month echocardiography. One-month follow-up MDCT data were available 
in 143 patients. Large PE was observed in 2 (1%) patients, moderate PE in 2 (1%) and small 
PE in 130 (91%) patients. In 105 patients, MDCT and echocardiography agreed on the PE 
grade while in the remaining 38 patients, MDCT and echocardiography disagreed (Table 
2). In 29 patients, MDCT considered PE grade more severe than echocardiography: 26 
patients with no PE on echocardiography had small PE on MDCT, 1 patient with small 
PE on echocardiography was considered having moderate PE on MDCT and 2 patients 
with small and moderate PE were considered having large PE on MDCT. Interestingly, 
patients with moderate or large PE at 1-month follow-up MDCT were hemodynamically 
stable and clinically asymptomatic and therefore pericardiocentesis was not performed. 
Among the remaining 9 patients, 7 patients with small PE on echocardiography did not 
show PE on MDCT and 2 patients with moderate PE on echocardiography were consid-
ered small PE on MDCT.
dISCUSSION
Significant PE early after TAVI is an uncommon complication and is more frequently 
observed after transapical TAVI. At follow-up, the incidence of new onset significant PE 
is also infrequent and is more frequently diagnosed with MDCT. Transthoracic echocar-
diography tends to underestimate the PE grade.
Prevalence of early and late pericardial effusion after TAVI
Clinically significant PE (including cardiac tamponade) is relatively infrequent after 
TAVI. While few registries report on the incidence of PE complicating TAVI(4,5,14), the 
incidence of new onset pericardial effusion at follow-up remains unknown. In 412 
consecutive patients undergoing TAVI between 2007 and 2010 (61% transarterial and 
39% transapical TAVI), Lange et al reported an incidence of early PE of 12.8%, including 
Table 2. Agreement between transthoracic echocardiography and MDCT to grade PE at 1 month follow-up 
after TAVI. The classification proposed by Weitzman et al.(13) has been used.
MdCT




None 2 26 0 0 28 (20%)
Small 7 102 1 1 111 (77%)
Moderate 0 2 1 1 4 (3%)
Large 0 0 0 0 0 (%)
Total 9 (6%) 130 (90%) 2 (1%) 2 (1%) 143
ECHO, echocardiography; MDCT, multidetector computed tomography; PE, pericardial effusion.
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2.6% of cardiac tamponade.(4) In the European Sentinel registry of TAVI, including 4571 
patients who underwent transfemoral (74.2%) or transapical (16.4%) TAVI, the incidence 
of cardiac tamponade was 2.4%.(5) These data contrast with the incidence reported 
by Rezq et al which was 4.3%.(14) In the current study, we reported an incidence of 
cardiac tamponade similar to that reported by Lange et al and Di Mario et al.(4,14) Dif-
ferences related to patient characteristics and procedural technique may account for 
the disparate incidences. For example, Rezq et al reported a higher incidence of cardiac 
tamponade among patients in whom a right ventricular screw-in lead was implanted 
compared with patients in whom a passive temporary pacemaker wire was used.(14) 
In addition, the use of stiff Amplatzer wires that provide excellent support during the 
deployment of the valve has been associated with LV tears that can cause fatal cardiac 
tamponade.(14) Careful manipulation of the wires and delivery systems within the LV 
is crucial to avoid this complication. Besides perforation of the RV or LV free walls by 
temporary pacemaker wires or delivery systems, other causes of cardiac tamponade 
include aortic annulus rupture after deployment of balloon-expandable valves, aortic 
dissection and complications of transapical access, such as LV tears. The majority of 
these causes leads to the development of cardiac tamponade immediately during the 
procedure or within few hours after the procedure.(14) In contrast, late PE after TAVI is 
less common and might be related with chronic aggressive anticoagulation treatments 
or post-pericardiotomy syndrome (in transapical TAVI). The incidence of new onset late 
PE in the present evaluation was 2.5% and was observed only in patients who underwent 
transapical TAVI. Importantly, hemodynamically significant late PE was not observed in 
any patient. The cause of this new onset PE at 1 month follow-up remains speculative, but 
post-pericardiotomy syndrome may be the most plausible cause since it was observed 
only in a patient undergoing transapical TAVI.
Multimodality imaging approach to evaluate pericardial effusion after TAVI
Echocardiography is the imaging technique of first choice to diagnose significant PE 
complicating TAVI. During the procedure, the use of transesophageal echocardiography 
permits immediate diagnosis of PE and cardiac tamponade. However, the number of 
TAVI procedures that are being performed with sedation instead of general anaesthesia 
is growing and the only imaging modality that can be used is transthoracic echocar-
diography. The present study highlights the discrepancies between transthoracic echo-
cardiography and MDCT in grading PE. Late after TAVI, transthoracic echocardiography 
underestimated the PE grade compared with MDCT. This observation may be relevant 
in patients who underwent transapical TAVI in whom a suboptimal acoustic window 
may challenge the diagnosis. Compared to transthoracic echocardiography, MDCT may 
provide higher diagnostic accuracy for loculated PE and permits differentiation between 
subepicardial fat and PE. In addition, MDCT may elucidate the cause of late new onset PE 
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such as pseudoaneurysms of the LV apex after transapical TAVI.(15) However, large PEs 
are hardly missed by transthoracic echocardiography which provides also hemodynamic 
assessment of cardiac function and permits accurate diagnosis of cardiac tamponade.
Limitations
Some limitations should be acknowledged. The present evaluation concerns retrospec-
tive analysis of data clinically acquired in a single center. The number of patients diag-
nosed with moderate or severe PE was small. The percentage of patients undergoing 
transapical TAVI was considerably high and therefore, the results of the present study 
may not be generalizable.
CONCLUSIONS
Significant PE early after TAVI is infrequent. The prevalence of small and moderate PE 
remains stable at 1 month follow-up. MDCT refines the diagnosis of significant PE. The 
clinical implications of the discrepancies in the quantification of PE between imaging 
modalities remain unclear. Further studies are needed to elucidate which patients 
should be evaluated with MDCT to diagnose the presence and cause of significant PE at 
follow-up.
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AbSTRACT
background: Elderly patients with severe aortic stenosis undergoing transcatheter 
aortic valve implantation (TAVI) often have increased calcification and fibrosis of the 
aorta. Indices that account for the severity of valvular obstruction and systemic vascular 
impedance may better assess the total left ventricular afterload. The present study 
evaluated changes in valvulo-arterial impedance (Zva), systemic arterial compliance and 
systemic vascular resistance after TAVI and investigated the prognostic value of these 
parameters. Methods: A total of 116 patients (49% men, 81±8 years) with symptomatic 
severe aortic stenosis underwent TAVI. Zva, systemic arterial compliance and systemic 
vascular resistance were measured at baseline, 1 and 12 months after TAVI. The primary 
endpoint was all-cause mortality. Results: After TAVI, there was a significant reduction 
in Zva (from 5.40±1.52 mmHg/mL/m2 at baseline to 4.13±1.17 at 1 month and to 4.35±1.38 
at 1 year, p < 0.001). Systemic arterial compliance (from 0.57±0.27 ml/m2/mmHg to 
0.57±0.28 and to 0.53±0.27; p = 0.408) and systemic vascular resistance (from 1938±669 
dyne.s.cm-5 to 1856±888 and to 1871±767; p = 0.697) did not change significantly over 
time. During a median follow-up of 25 months, survival rates of patients with baseline 
Zva ≥5 mmHg/mL/m2 were lower compared with patients with Zva <5 mmHg/mL/
m2 (82% vs. 91%, respectively; log-rank p = 0.04). On multivariate Cox proportional 
hazards analysis, baseline Zva was independently associated with all-cause mortality 
(HR = 1.48, 95% CI = 1.05-2.07, p = 0.025).Conclusions: In patients undergoing TAVI there 
is a significant post-procedural reduction in Zva but not in systemic arterial compliance 
or vascular resistance. Baseline Zva is an independent predictor of overall mortality at 2 
years follow-up.
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INTROdUCTION
The PARTNER trial and many registries have confirmed the safety and efficacy of trans-
catheter aortic valve implantation (TAVI) in over 60,000 patients with symptomatic 
severe aortic stenosis and high risk or contraindications for surgery.(1-6) TAVI improves 
aortic valve hemodynamics, systolic left ventricular (LV) function and clinical outcome.
(7-10) In addition, significant regression in LV hypertrophy has been reported in 
patients with aortic stenosis following TAVI.(8,11) However, there is an important inter-
individual variability in LV mass regression following surgical aortic valve replacement. 
In particular, older patients tend to show less LV mass reduction and more impaired LV 
diastolic function after aortic valve replacement compared with younger patients.(12-
14) Sustained LV hypertrophy and diastolic dysfunction after aortic valve replacement 
have a negative impact on the long-term outcome of patients undergoing aortic valve 
replacement.(12) The lack of a straightforward relationship between stenosis-dependent 
pressure overload relief and LV mass reduction after aortic valve replacement has led to 
further search for additional pathophysiological determinants of LV geometry and func-
tion after aortic valve replacement. For example, sustained reduced systemic arterial 
compliance may hinder the beneficial effects of aortic valve replacement on LV function 
and hypertrophy regression.(15) Older patients with calcific aortic stenosis often have 
reduced systemic arterial compliance due to concomitant arterial atherosclerosis and/
or medial elastocalcinosis. This reduced systemic arterial compliance contributes to 
increased LV afterload imposed by the valvular stenosis. The valvulo-arterial impedance 
(Zva) has been proposed to assess the global (i.e. valvular + arterial) load imposed to 
the LV.(16,17) Severely increased Zva has been associated with reduced survival in the 
aortic stenosis population treated conservatively.(18) Patients who are candidate for 
TAVI often have severely reduced systemic arterial compliance and increased Zva which 
can reduce early after TAVI.(19) However, the influence of Zva on TAVI outcomes has not 
been explored. The objectives of the present study were two-fold: 1) to assess changes 
in Zva, systemic arterial compliance and systemic vascular resistance at 1 and 12 months 
following TAVI and 2) to assess the impact of baseline Zva on survival after TAVI.
METHOdS
Patient population
A total of 116 patients with severe symptomatic aortic stenosis (aortic valve area < 1.0 
cm2 or transaortic mean pressure gradient ≥40 mmHg) who underwent TAVI in two 
centers (84 patients in the Leiden University Medical Center, Leiden, The Netherlands 
and 32 patients in the Québec Heart and Lung Institute, Department of Medicine, Laval 
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University, Québec, Canada) were included in the present study. Patients who under-
went transcatheter valve-in-valve procedures or in whom baseline Zva could not be 
derived were excluded. Based on the evaluation of a multidisciplinary team, patients 
were considered for TAVI due to high predicted operative risk or contraindications for 
conventional surgical aortic valve replacement.(20) According to the institutional pro-
tocols, patients underwent comprehensive clinical and echocardiographic evaluation 
prior to TAVI. In addition, invasive coronary angiography was performed to rule out 
significant coronary artery disease amenable to percutaneous intervention.
Clinical and echocardiographic data were retrospectively analyzed. Clinical parameters 
included demographics, cardiovascular risk factors, clinical symptoms, medications and 
operative mortality risk calculated according to the logistic European system for cardiac 
operative risk evaluation (EuroSCORE I).(21) Non-invasive parameters of aortic stenosis 
severity and vascular resistance, including Zva and systemic arterial compliance, were 
measured and the changes in these parameters at short- and mid-term follow-up after 
TAVI were evaluated. In addition, the independent associations of these parameters with 
TAVI outcomes were investigated.
Echocardiography
Transthoracic echocardiography (TTE) was performed at baseline with commercially 
available ultrasound systems (Vivid 7, E9, General Electric, Horten, Norway; ie33 Phillips 
Medical Systems). The aortic valve anatomy (bicuspid or tricuspid) was evaluated in 
the parasternal short-axis view. Aortic jet velocity was evaluated in multiple acoustic 
windows, adjusting gain, wall filter, baseline and scale of continuous wave Doppler 
recordings to optimize the signal. The LVOT velocity was measured in the apical long-
axis or 5-chamber views from the pulsed wave Doppler spectral signal.(22) Aortic valve 
area (AVA) was calculated with the continuity equation.(22) Severe aortic stenosis was 
considered when the AVA was <1.0 cm2 and/or the transaortic mean gradient was ≥40-
50 mmHg.(23,24) Left ventricular (LV) end-diastolic (LVEDV) and end-systolic volumes 
(LVESV) were measured according to the biplane Simpson’s method and these measures 
were used to calculate the LV ejection fraction (LVEF).(25) Standard LV linear dimensions 
and LV mass were also measured according to current recommendations.(25) Finally, 
LV stroke volume was measured in the LV outflow tract from the pulsed wave Doppler 
recordings and indexed to body surface area (SVi).
Measurement of systemic arterial compliance, valvulo-arterial impedance and 
systemic vascular resistance
Systemic arterial compliance was calculated as the ratio of LV SVi to pulse pressure as 
previously described.(26) Systemic arterial pressure was measured with an arm-cuff 
sphygmomanometer at the time of echocardiography and the pulse pressure was cal-
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culated from the difference between systolic and diastolic arterial pressures. In addition, 
global LV hemodynamic load was estimated with the use of the Zva calculated from the 
formula: (systolic arterial pressure + transaortic mean gradient)/SV index.(16) Based on 
previous studies, LV global load was considered to be severely increased when the value 
of Zva was ≥5 mm Hg/ml/m2.(16) Moreover, systemic vascular resistance was calculated 
with the formula: (80 × mean arterial pressure)/cardiac output.(16,18)
TAVI procedure
At the catheterization laboratory or hybrid operating room, an Edwards SAPIEN pros-
thetic valve (Edwards Lifesciences Inc., CA, USA) of either 23 mm or 26 mm size was 
implanted under general anesthesia. Prosthesis size selection was based on dimensions 
of the aortic valve annulus as assessed with transesophageal echocardiography or mul-
tidetector row computed tomography, if available. Either a transapical or transfemoral 
approach was used, based on the peripheral artery anatomy as assessed with imaging of 
the ilio-femoral arteries and aorta.(27) The technique included rapid ventricular pacing 
during balloon dilatation of the native aortic valve and deployment of the balloon-
expandable prosthetic valve.(27) Transesophageal echocardiography complemented 
fluoroscopy for better guidance of the procedure. Procedural success was defined as 
successful implantation of a functioning aortic prosthesis without intra-procedural 
mortality.
Follow-up
Clinical and echocardiographic follow-up was scheduled at 1 and 12 months after TAVI. 
Clinical evaluation included New York Heart Association (NYHA) functional class and 
complete TTE was performed to assess prosthetic valve hemodynamics, LV dimen-
sions and function as well as Zva, systemic arterial compliance and systemic vascular 
resistance. Paravalvular aortic regurgitation was evaluated at one month follow-up and 
was graded none or trivial (0-1), mild (2+), moderate (3+) or severe (4+), according to 
recommendations. (28) In addition, all-cause mortality was recorded during follow-up.
Statistical analysis
Statistical analyses were performed using SPSS software version 17, (SPSS Inc., Chicago, 
IL, USA) and STATA software, version 11 (Stata Corp, College Station, TX, USA). Continu-
ous variables are presented as mean and standard deviation if normally distributed, as 
determined by visual inspection of their histogram, or median and interquartile range 
otherwise. Categorical variables are presented as frequencies and percentages. Continu-
ous variables were compared using unpaired Student’s t-test or the Mann-Whitney test 
where appropriate, whereas categorical variables were compared with the χ2 test or 
Fisher’s exact test, as appropriate. Changes in continuous variables in overall population 
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from baseline to follow-up were analyzed with repeated measures analysis of variance 
(ANOVA), and Bonferroni’s correction was used for post-hoc analysis of significant re-
sults. In addition, patients were dichotomized according to a baseline value of Zva ≥5 
mmHg/ml/m2 or <5 mmHg/ml/m2. One-way ANOVA analysis for repeated measures was 
used to compare echocardiographic changes between groups. Cumulative events rates 
were calculated using the Kaplan-Meier method for patients with a Zva ≥5 mmHg/ml/m2 
and patients with a Zva <5 mmHg/ml/m2 at baseline. The log-rank test for time-to-event 
data with respect to all-cause mortality endpoint was used for statistical comparison 
between 2 patient groups. Additionally, univariate and multivariate Cox proportional 
hazards models were performed to identify independent determinants of all-cause 
mortality. The estimated hazard ratios and the 95% confidence intervals were obtained. 
Univariate variables with a p < 0.2 were included in the multivariate model. A two-sided 
p < 0.05 was considered statistically significant.
RESULTS
A total of 116 patients with severe symptomatic aortic stenosis (mean age 81±8 years old, 
49% men) were evaluated. All patients underwent successful TAVI using a transfemoral 
(n = 48, 41%) or transapical (n = 68, 59%) approach. Thirty-five patents (30%) received a 
23-mm valve prosthesis and 81 (70%) received a 26-mm valve. Clinical and procedural 
characteristics are outlined in Table 1.
Table 1. Patient characteristics
Variable N = 116
Age (years) 81±8
Male, n (%) 57(49%)
BSA (m2) 1.78±0.20
Renal dysfunction (Creatinine>1.2 mg/dl) 41(35%)
Hypertension, n (%) 48 (41%)
Hypercholesterolemia, n (%) 63 (54%)
Diabetes, n (%) 32 (27%)
Peripheral vascular disease, n (%) 26(22%)
Smoking, n (%) 40 (35%)
Coronary artery disease, n (%) 75 (65%)
NYHA functional class III-IV, n (%) 85 (73%)
Pacemaker, n(%) 8 (7%)
Atrial fibrillation, n (%) 27 (23%)
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Changes in aortic valve hemodynamics and global LV load after TAVI
During the first postoperative month, 7 (6%) patients died and 3 additional patients died 
within the first postoperative year. Overall 21 patients died during a median follow-up of 
25 months follow-up (interquartile range: 13-45 months) and there were no patients lost 
at follow-up. Echocardiographic assessment was available in 109 patients at first month 
follow-up and complete data (baseline, 1 and 12 months after TAVI) were available in 100 
patients. Six patients had been followed-up for less than 12 months.
Table 2 summarizes the changes in aortic valve hemodynamics, LV dimensions and 
function, Zva, systemic arterial compliance or vascular resistance. As expected, AVA 
significantly increased (from 0.67±0.17 cm2 to 1.86±0.49 cm2 at 1 month follow-up and 
remained stable at 12 months follow-up: 1.81±0.61 cm2, p < 0.001) and transaortic mean 
pressure gradient significantly decreased after TAVI (baseline 42±15 mmHg to 8±3 mmHg 
and 9±5 mmHg at 1 and 12 months follow-up, respectively; p < 0.001). LVEF increased 
slightly from 54±14% to 55±13% at 1 month and to 56±11% at 12 months (p = 0.051). There 
was a significant reduction in Zva (from 5.40±1.52 mmHg/mL/m2 to 4.13±1.17 mmHg/
mL/m2 at 1 month follow-up and remained stable at 12 months: 4.35±1.38 mmHg/mL/
m2, p < 0.001) (Figure 1). In contrast, systemic arterial compliance did not change sig-
nificantly (from 0.57±0.27 ml/m2/mm to 0.57±0.28 ml/m2/mmHg and to 0.53±0.27 ml/m2/
mmHg, p = 0.408) (Table 2). Similarly, systemic vascular resistance did not change over 
time (from 1938±669 dyne.s.cm-5 to 1856±888 dyne.s.cm-5 and to 1871±767 dyne.s.cm-5, 
p = 0.697).
In addition, the incidence of paravalvular aortic regurgitation was evaluated at 1 
month follow-up. None or trivial PAVR was observed in 82%, mild in 17 (16%) and severe 
in 2 (2%) patients.










Logistic EuroSCORE I 21.2±12.3






Abbreviations: BSA=Body surface area; NYHA=New York Heart Association; TAVI: transcatheter aortic valve 
implantation
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Table 2. Changes in echocardiographic parameters after TAVI
baseline 1 month 12 months p- value
AVA (cm2) 0.67±0.17 1.86±0.49 1.81±0.61 <0.001
MG (mmHg) 42±15 8±3 9±5 <0.001
LVEDV (ml) 117±45 117±45 110±41 0.065
LVESV(ml) 56±38 55±39 48±29 0.002
LV SV index(ml/m2) 34±10 34±9 35±11 0.725
LVEF (%) 54±14 55±13 56±11 0.051
LV mass (g) 232±60 224±66 201±47 <0.001
Zva (mmHg/mL/m2) 5.40±1.52 4.13±1.17 4.35±1.38 <0.001
Zva5≥ mmHg/mL/m2, (%) 57% 24% 24% <0.001
SAC (ml/m2/mmHg) 0.57±0.27 0.57±0.28 0.53±0.27 0.408
SAC<0.6 ml/m2/mmHg, (%) 67% 67% 71% 0.456
SVR (dyne.s cm-5) 1938 ± 669 1856 ±888 1871 ± 767 0.697
SAC>2000 dyne.s cm-5, (%) 37% 26% 34% 0.642
SBP (mmHg) 133±23 138±24 142±23 0.001
DBP (mmHg) 69±12 69±10 70±13 0.914
PP (mmHg) 64±20 69±22 73±21 0.453
Cardiac output (L/min) 4.0±1.2 4.4±1.3 4.5±1.4 0.033
Abbreviations: AVA=aortic valve area; DBP=diastolic blood pressure LV=left ventricle; LVEDV=left ven-
tricular end-diastolic volume; LVEF= LV Ejection Fraction; LVESV=left ventricular end-systolic volume 
MG=mean gradient; PP= pulse pressure; SAC=systemic arterial compliance; SBP= systolic blood pressure; 
SVR=systemic vascular resistance; Zva=valvulo-arterial impedance
Figure 1. Mean values of global LV afterload (Zva) at baseline, 1 month and 12 months follow-up (unit 
mmHg/mL/m2).
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Changes in symptoms and global LV load after TAVI according to baseline Zva
At baseline, 68 (57%) patients had a Zva ≥5 mmHg/ml/m2. Table 3 outlines the differ-
ences in clinical and echocardiographic parameters between patients with baseline Zva 
≥5 mmHg/ml/m2 and patients with Zva <5 mmHg/ml/m2. Patients with baseline Zva ≥5 
mmHg/ml/m2 had smaller AVA (0.65±0.18 cm2 vs. 0.73±0.18 cm2 p = 0.020), lower systemic 
arterial compliance (0.45 ± 0.15 ml/m2/mmHg vs. 0.72±0.29 ml/m2/mmHg; p < 0.001), 
smaller LVEDV (105±34 ml vs. 133±50 ml, p = 0.001), lower SVi (28±6 ml/m2 vs. 41±9 ml/m2, 
Table 3. Baseline clinical and echocardiographic parameters of patients with Zva≥5 mmHg/mL/m2 versus 
patients with Zva<5 mmHg/mL/m2 at baseline
Zva ≥5 (n = 68) Zva <5 (n = 48) p-value
Age (years) 80 ± 9 82 ± 8 0.303
Male, n (%) 30 (44) 27(56) 0.198
BSA (m2) 1.8±0.2 1.75±0.21 0.310
Diabetes n (%) 18 (27) 14 (29) 0.749
Renal dysfunction n (%) 21 (31) 20 (42) 0.231
Hypertension n (%) 33 (49) 15 (31) 0.063
Coronary artery disease n (%) 31(27) 44 (38) 0.989
Pacemaker n (%) 3 (4) 5 (10) 0.238
Atrial fibrillation n (%) 20 (29) 7 (14) 0.063
NYHA III-IV n (%) 47 (69) 38 (79) 0.228

















AVA (cm2) 0.65±0.18 0.73±0.18 0.020
MG (mmHg) 42±16 41±16 0.664
PG (mmHg) 67±22 65±23 0.726
LVEDV (ml) 105±34 133±50 0.001
LVESV (ml) 53±36 61±42 0.335
LVEF ≤35% 12(18%) 5(10%) 0.278
SVi (ml/ m2) 28±6 41±9 <0.001
SVi≤35 ml/ m2 61(89%) 11(23%) <0.001
SAC (ml/ m2/mmHg) 0.45 ± 0.15 0.72±0.29 <0.001
SBP (mmHg) 137±24 128±22 0.040
PP (mmHg) 65±20 61±18 0.181
SVR (dyne.s cm-5) 2192 ± 709 1579± 455 0.005
LV mass (g) 235±74 231±74 0.788
Cardiac output (L/min) 3.6 4.7 <0.001
Abbreviations: see table 2
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p < 0.001) and higher systemic vascular resistance (2192 ± 709 dyne.s.cm-5 vs. 1579± 455 
dyne.s.cm-5, p = 0.005) compared with patients with Zva <5 mmHg/ml/m2.
The percentage of patients with low gradient aortic stenosis (mean gradient <40 
mmHg) was similar in patients with Zva ≥5 mmHg/mL/m² and patients with Zva <5 
mmHg/mL/m² (33 [48%] vs. 23 [48%], respectively; p = 0.948). The percentage of patients 
with low gradient aortic stenosis and preserved LVEF (≥50%) was also similar between 
groups (17 (25%) in patients with Zva ≥5 mmHg/mL/m² vs. 16 (33%) in patients with Zva<5 
mmHg/mL/m², p = 0.327).
Overall 86 (86%) of patients that were followed up at 12 months improved their func-
tional capacity by at least 1 grade. There was no difference in the proportion of patients 
that improved clinically between the group of patients with a baseline Zva ≥5 mmHg/mL/
m² and patients with Zva <5 mmHg/mL/m² (50 [85%] vs. 36 [86%]), respectively; p = 0.944).
In terms of echocardiographic outcomes, patients with baseline Zva <5 mmHg/mL/m² 
showed a significant reduction in LVEDV as compared with patients with Zva ≥5 mmHg/
mL/m² (from 133±52 ml to 122±55 ml and to 111±50 ml at 1 and 12 months follow-up vs. 
104±32 ml to 113±35 ml and to 109±32 ml, respectively; p = 0.001). Interestingly, patients 
with baseline Zva ≥5 mmHg/mL/m² showed a significant improvement in LVEF (from 
52±14% to 54±13% and to 57±11% at 1 and 12 months follow-up vs. 55±13% to 56±13% 
and to 55±11%, respectively; p = 0.037) and SVi (from 28±6 ml/m2 to 33±9 ml/m2 and to 
35±8 ml/m2 at 1 and 12 months follow-up vs. 41±9 ml/m2 to 37±7 ml/m2 and to 36±10 ml/
m2, respectively; p < 0.001) (Table 4). A subanalysis focused on 72 patients with baseline 
SVi≤35 ml/ m2 showed no differences in remodeling between groups (Table 5).
Table 4. Changes in echocardiographic parameters according to ZVa values







baseline 1 month 12 
months
baseline 1 month 12 
months
LVEDV(ml) 104±32 113±35 109±32 133±52 122±55 111±50 0.089 0.001
LVESV(ml) 52±32 51±32 44±24 60±44 58±47 51±32 0.306 0.065
LVEF (%) 52±14 54±13 57±11 55±13 56±13 55±11 0.740 0.037
LV mass(g) 228±71 219±62 200±49 237±72 231±71 203±55 0.510 0.562
SVi (ml/m2) 28±6 33±9 35±8 41±9 37±7 36±10 0.001 0.001
SAC (ml/m2/
mmHg)
0.45±0.16 0.51±0.24 0.52±0.21 0.73±0.29 0.65±0.30 0.52±21 0.356 0.002
SVR (dyne.s 
cm-5)
2194±689 1971±899 1937±822 1605±469 1707±861 1785±690 0.001 0.087
SBP (mmHg) 137±26 135±18 140±24 126±28 130±29 139±28 0.470 0.442
Cardiac output 
(L/min)
3.6±0.9 4.3±1.4 4.5±1.5 4.6±1.38 4.7±1.2 4.5±1.3 0.015 0.007
Abbreviations: see table 2.
Impact of valvulo-arterial impedance on 2-year outcome of patients undergoing transcatheter aortic valve implantation 89
Effect of baseline Zva on all-cause mortality
During a median follow-up of 25 months (interquartile range: 13-45 months), a total of 
21 (18%) patients died. The Kaplan–Meier curves show the survival rates for patients di-
vided according to the baseline Zva value (≥5 mmHg/ml/m2 vs. <5 mmHg/m/ m2) (Figure 
2). The survival rates at 1 and 2 years follow-up in the group of patients with baseline Zva 
≥5 mmHg/mL/m2 were 88% and 82% respectively, compared with the 96% and 91%, for 
the group of patients with Zva <5 mmHg/mL/m2 (log-rank p = 0.04). From the univariate 
Cox proportional hazards analysis, baseline values of Zva (HR = 1.52 95% CI = 1.16-1.99, 
p = 0.002), LV mass (HR = 1.00, 95% CI = 0.99-1.01, p = 0.118) and systemic vascular resis-
tance (HR = 1.05 per each 100 dyne.s cm-5 increase, 95% CI = 1.01-1.11, p = 0.044) were 
selected to be included in the multivariable analysis (Table 6). In the multivariate model 
only baseline Zva was independently associated with all-cause mortality (HR = 1.48, 95% 
CI = 1.05-2.07, p = 0.025).
Table 5. Changes in echocardiographic parameters in 72 patients with baseline SVi≤35 ml/m2







baseline 1 month 12 
months
baseline 1 month 12 
months
LVEDV (ml) 102±30 111±34 109±33 105±61 111±61 112±56 0.859 0.829
LVESV (ml) 52±30 50±29 44±23 57±60 57±54 52±37 0.447 0.119
LVEF (%) 52±14 55±13 58±11 51±19 56±16 53±13 0.128 0.283
SVi (ml/m2) 27±5 33±9 33±9 30±7 35±6 36±15 0.416 0.835
LV mass (g) 222±68 216±61 198±50 200±68 203±64 201±54 0.113 0.059
Abbreviations: see table 2.




The present study showed that TAVI leads to improved valvular hemodynamics, with 
significant reductions in systolic pressure gradients and increase in aortic valve area, and 
significant reduction in LV global pressure overload, as measured with Zva. In contrast, 
systemic arterial compliance and systemic vascular resistance did not change sig-
nificantly following TAVI. Baseline Zva was independently associated with late outcomes 
(all-cause mortality) after TAVI.
Changes in global LV pressure afterload in patients undergoing TAVI
TAVI leads to improved aortic valve hemodynamics and LV systolic function, significant 
reductions in LV mass and improved survival.(7-9,29) In terms of valvular hemodynamic 
improvements, the majority of previous series have evaluated systolic transvalvular 
pressure gradients and aortic valve area. However, valvular parameters reflect only one 
aspect of the LV hemodynamic load.(16) Systemic arterial compliance and vascular 
resistance are important contributors to increased LV hemodynamic load in patients 
with aortic stenosis. The Zva is a valid marker of global LV hemodynamic burden in 
these patients.(16) The present study shows that the majority of patients with severe 
aortic stenosis undergoing TAVI had a markedly increased Zva (≥5 mmHg/mL/m2) which 
significantly decreased after TAVI. This reduction was mainly determined by a significant 
Table 6. Univariate and multivariate Cox proportional hazards model to predict all-cause mortality
Variable Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Zva (per 1 mmHg/mL/m2 increase) 1.52 (1.16-1.99) 0.002 1.48 (1.05-2.07) 0.025
Male 1.42 (0.60-3.38) 0.421
Diabetes 1.66 (0.66-4.18) 0.279
Renal dysfunction 1.01 (0.42-1.46) 0.982
Coronary artery disease 0.64 (0.26-1.53) 0.319
Aortic mean gradient (per 1 mmHg increase) 0.99 (0.96-1.02) 0.515
LVEF (per 1% increase) 0.99 (0.96-1.02) 0.759
LVEDV (per 1 ml increase) 0.99 (0.98-1.00) 0.691
NYHA ≥III 1.54 (0.44-5.34) 0.493
LV mass (per 1 g increase) 1.00 (0.99-1.01) 0.118 1.00 (0.99-1.01) 0.075
SAC (per 1 ml/m2/mmHg increase) 0.51(0.07-3.47) 0.429
SVR (per 100 dyne.s cm-5 increase) 1.05 (1.01-1.11) 0.044 1.01 (0.93-1.10) 0.711
Log Euroscore (%) 0.97 (0.94-1.01) 0.245
Abbreviations: LV=Left ventricle, LVEF=LV ejection fraction; LVEDV=LV end-diastolic volume; NYHA=New 
York Heart Association; SAC=systemic arterial compliance; SVi= stroke volume index; SVR=systemic vascu-
lar resistance; Zva=valvulo-arterial impedance.
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increase in AVA and associated decrease in gradient and not by an improvement in sys-
temic arterial compliance or vascular resistance. Indeed, these vascular hemodynamic 
parameters were severely abnormal in the vast majority of the patients at baseline and 
remained unchanged after TAVI. These results were expected since patients undergoing 
TAVI may have significant arterial atherosclerosis and/or medial elastocalcinosis that 
lead to impaired systemic arterial compliance and increased vascular resistances. The 
TAVI procedure only addresses the valvular problem and not the vascular pathologic 
processes. Hence it is unlikely that TAVI yields normalization of systemic arterial compli-
ance and systemic vascular resistance in elderly patients with associated co-morbidities, 
such as chronic renal dysfunction, hypertension and diabetes. Similar results were 
described by Giannini et al in a series of 102 patients undergoing TAVI,(19) in which sig-
nificant reductions in Zva were observed early after TAVI.(19) In contrast, the authors also 
reported significant acute improvement in systemic arterial compliance and reduction 
in systemic vascular resistance. These conflicting results may be explained by the differ-
ences in the baseline characteristics of the patient populations. The study population of 
Giannini and coworkers included a higher proportion of patients with impaired baseline 
LVEF and the vascular arterial hemodynamics (i.e. systemic arterial compliance and 
vascular resistance) were impaired to a lesser extent in the study of Giannini et al. than 
in the present population. These findings suggest that the presence of more advanced 
vascular disease may limit the beneficial effects of aortic valve replacement.
Valvulo-arterial impedance to predict prognosis after TAVI
Previous studies have demonstrated the prognostic value of Zva in asymptomatic 
aortic stenosis patients with preserved LV ejection fraction.(18,30,31) However, a recent 
multicenter study of patients with low-ejection fraction, low-gradient aortic stenosis 
reported that Zva did not have incremental prognostic value.(32) In this subgroup of 
patients, Zva may not be an accurate parameter to estimate global LV afterload since 
subtle changes in SVi or heart rate may cause significant variations in Zva.(33) However, 
the prognostic value of Zva remains unknown in patients with increased operative risk 
or contraindications for surgical aortic valve replacement who are candidates for TAVI. In 
the study by Giannini et al. patients who died early after TAVI had higher Zva compared 
with patients who were alive at 6 months after TAVI.(19) The present study further dem-
onstrates that Zva at baseline is an independent predictor of all-cause mortality in severe 
aortic stenosis patients treated with TAVI. These results are in agreement with the study 
by Hachicha et al where Zva was also an independent determinant of clinical outcome 
regardless of the treatment (surgical aortic valve replacement or medical treatment).
(34) Zva remained independently associated with increased mortality despite adjusting 
for systemic vascular resistance, thereby suggesting that other factors may contribute 
to this association. Indeed, high baseline Zva may reflect severe valvular disease and 
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hemodynamic load that may not be completely corrected by TAVI. Patients with high 
Zva often have smaller LV cavity and aortic annulus and potentially more calcified aortic 
valve cusps and may be at higher risk for prosthesis-patient mismatch, i.e. residual aortic 
stenosis after TAVI.(9,35) Finally, high Zva may be a marker of more advanced myocardial 
fibrosis and dysfunction. Herrmann et al. have reported that Zva correlates well with 
the extent of myocardial fibrosis and systolic longitudinal shortening.(36) Patients 
with severe myocardial fibrosis and associated impaired LV longitudinal kinetics had 
higher mortality and less improvement of symptomatic status after surgical aortic valve 
replacement.
Clinical implications of implementing valvulo-arterial impedance measurement 
in routine clinical practice
So far, current guidelines recommend aortic valve replacement in patients with severe 
symptomatic aortic stenosis as defined by AVA, mean transaortic pressure gradient and 
maximum peak systolic velocity.(23) However, these hemodynamic parameters reflect 
only one component of the global (i.e. valvulo-arterial) LV pressure overload. Systemic 
arterial compliance and vascular resistance are not taken into consideration in current 
guidelines. In elderly patients with high prevalence of hypertension, coronary artery 
disease and atherosclerosis, the inclusion of these parameters may help to refine risk 
stratification. In patients who are deemed not operable, TAVI is a feasible and safe thera-
peutic alternative. However, in order to improve the outcomes of this therapy, accurate 
patient selection is crucial. The inclusion of Zva in the risk stratification may help to 
identify the patients who may be at higher risk for poor outcome following TAVI. Ad-
ditional studies are warranted to elucidate whether the inclusion of a measure of global 
LV hemodynamic load, such as Zva, in clinical operative risk scores may help to improve 
the outcomes of patients undergoing TAVI.
Limitations
The present patient population and the number of patients reaching the endpoint are 
rather small. In addition, the study design is retrospective. In addition, assessment of 
pseudo-severe aortic stenosis with stress echocardiography was not systematically 
performed. Atrial fibrilation was more commonly observed in the group of patients 
with Zva ≥5 mmHg/mL/m². Although in these patients SVi was averaged from several 
heart beats, calculation of Zva is flow-dependent and a systematic error may have been 
introduced. Furthermore procedural complications were not evaluated according to 
Valve Academic Research Consortium criteria. The present results need to be confirmed 
in larger series of patients and the impact of Zva on TAVI outcomes should be validated 
in a prospective study.
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CONCLUSIONS
In patients undergoing TAVI there is a significant post-procedural reduction in Zva but 
not in systemic arterial compliance or vascular resistance. High baseline Zva is an inde-
pendent predictor of increased all-cause mortality at 2-year follow-up. Further studies 
are needed to identify the role of the routine measurement of ZVa for the identification 
of patients who have a high likelihood to benefit from TAVI.
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Patients with severe aortic stenosis undergoing transcatheter aortic valve implantation 
(TAVI) often have concomitant significant mitral regurgitation (MR). Quantification and 
time course characterization of changes in MR after TAVI remain unexplored. The pres-
ent study evaluated quantitatively assessed changes of significant MR after TAVI.
Fifty-nine patients (age 82±6 years, male 41%) with severe aortic stenosis and mild 
or more MR undergoing TAVI were evaluated retrospectively. All patients underwent 
pre-discharge echocardiography and 44 underwent repeat echocardiography at 12 
months follow-up. Mitral regurgitation was quantitatively assessed. Improvement in MR, 
defined as ≥30% reduction in effective regurgitant orifice area (EROA), was assessed in 
the pre-discharge echocardiogram or at 12 months follow-up. Mitral regurgitant volume 
reduced from 35.6[2.2] to 18.0[1.8] and to 17.5[2.4] ml (p < 0.001), EROA from 20.5 [1.1] to 
13.9[1.2] and to 10.6[1.2] mm2 (p < 0.001) and vena contracta from 5.0 [0.15] to 3.8 [0.18] and 
to 3.5 [0.24] mm (p < 0001) immediately after TAVI and at 12 months, respectively. Overall, 
35 (59%) patients showed a pre-discharge improvement in MR and an additional 10 (17%) 
improved by 12 months post-TAVI. In multivariable analysis, baseline EROA (odds ratio 
1.095, 95% confidence interval: 1.013-1.185, p = 0.023) and predominantly functional MR 
(odds ratio 4.714, 95% confidence interval: 1.105-20.112, p = 0.036) were independently 
related to acute postoperative improvement. In conclusion, immediately after TAVI, a 
significant improvement in MR is observed in two-thirds of patients undergoing TAVI 
and in an additional one-fifth at 12 months follow-up. Baseline EROA and predominantly 
functional MR pathology are associated with pre-discharge postoperative MR improve-
ment.
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INTROdUCTION
The prevalence of severe mitral regurgitation (MR) among patients with severe aortic 
stenosis undergoing transcatheter aortic valve implantation (TAVI) ranges between 
1-9%.(1-4) Preoperative severe MR has been associated with poor short-term outcome 
after TAVI.(1-5) However, spontaneous reduction of MR after the procedure has also been 
demonstrated.(1,2,5-7) The time course of changes in MR after TAVI and the prognostic 
implications of these changes remain controversial.(1-3) Reasons for discrepant results 
may include non-systematic approach to quantify MR severity (semi-quantitative versus 
quantitative measurements), timing of assessment of MR after TAVI (short versus long-
term follow-up) and underlying mechanism of MR (functional versus degenerative).
Time course characterization of changes in MR and investigation of the determinants 
of improvement in MR after TAVI may significantly aid the decision making of patients 
with severe aortic stenosis and concomitant significant MR. For patients in whom MR 
is expected to persist after TAVI the option of combined aortic and mitral valve surgery 
may need to be considered despite the increased surgical risk.(8,9) Alternatively, a com-
bined TAVI and transcatheter mitral valve repair approach could be performed.(10,11) 
However, for patients with MR of borderline significance, the progression after TAVI is 
also ambiguous.(3) Hence, it is compelling to know which TAVI candidates will improve 
their MR after the procedure in order to optimize their selection for TAVI and overall 
management.
The present study evaluated changes in MR after TAVI in patients with symptomatic 
severe aortic stenosis and mild or more MR. The association between baseline clinical 
and echocardiographic parameters – including quantitative measurements of MR sever-
ity- and changes in MR was evaluated.
MATERIAL ANd METHOdS
From an ongoing registry of patients with symptomatic severe aortic stenosis and 
excessive risk or contraindications for cardiac surgery who were treated with TAVI,(12) 
59 patients with concomitant mild or more MR were included in the present evaluation. 
Patients with mechanical mitral valves, mitral valve annuloplasty and bioprosthetic 
aortic valves, as well as patients with a valve-in-valve as a bailout procedure after TAVI 
were excluded.
Following institutional protocols, patients referred for TAVI underwent careful clinical 
evaluation and a comprehensive transthoracic echocardiographic analysis. After suc-
cessful TAVI, patients underwent echocardiographic follow-up pre-TAVI, pre-discharge 
and at 12 months. Demographic, clinical and echocardiographic information were 
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prospectively collected in an electronic clinical file (EPD vision version 8.3.3.6; Leiden, 
The Netherlands) and retrospectively analyzed. Changes in MR during follow-up were 
retrospectively examined and among various baseline clinical and echocardiographic 
parameters, independent correlates of post-TAVI MR improvement were investigated. 
The institutional review board approved the study and waived the need for patient writ-
ten informed consent for retrospective analysis of clinically acquired data.
TAVI was performed in the catheterization laboratory under general anesthesia. The 
procedure was guided by fluoroscopy and additionally assisted by transesophageal 
echocardiography (iE33, Philips Medical System, Andover, MA, USA). Patients were 
treated with balloon-expandable (Edwards Sapien or Sapien XT, Edwards Lifescience, 
Irivine, CA) or self-expandable (CoreValve system, Medtronic, Minneapolis, MN) valves. 
Adequate valve sizing was based on multi-detector row computed tomography (MDCT) 
measurements of the aortic annulus. Coronary angiography was performed in all 
patients and percutaneous coronary interventions were performed when indicated. 
Transfemoral approach was applied in all patients treated with the CoreValve prosthesis. 
In patients treated with balloon-expandable valves, transfemoral approach was the first 
choice and the transapical approach was performed in cases where the anatomy of 
the ilio-femoral arteries was not considered suitable.(13) Under rapid right ventricular 
pacing, the native aortic valve was first dilated and thereafter, the balloon-expandable 
device was implanted. For the self-expandable prosthesis, rapid right ventricular pacing 
was not systematically performed. At this point, the post-procedural aortic regurgitation 
was assessed. In cases of significant paravalvular leak a post-dilatation of the implanted 
prosthesis was performed.
A commercially available ultrasound system (Vivid 7, E9, General Electric Horten, 
Norway) equipped with 3.5 MHz or M5S transducers was used to obtain transthoracic 
baseline and follow-up echocardiographic data. Quantification of left ventricular (LV) 
dimensions and function and calculation of LV mass were performed according to 
recommendations.(14) Furthermore LV end-diastolic (LVEDV) and end-systolic (LVESV) 
volumes were measured in the apical 4- and 2-chamber views and according to Simp-
son’s method LV ejection fraction (LVEF) was derived.(14) The aortic valve morphology 
(bicuspid or tricuspid) was assessed in the parasternal short-axis view. The diameter of 
the LV outflow tract was measured in the parasternal long-axis view during mid-systole. 
Peak and mean transaortic pressure gradients were assessed in the apical long-axis 
and in the 5-chamber views. The aortic valve area was calculated with the continuity 
equation and the stenosis was considered severe if aortic valve area was <1.0 cm2 and 
the transaortic mean gradient was ≥40 mmHg.(9) Systolic pulmonary arterial pressures 
were also calculated according to current guidelines.(15) Color-Doppler echocardiog-
raphy was performed after optimization of the Nyquist limit and color gain settings. 
In order to diagnose and grade MR a multiparametric approach was used.(16) Effective 
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regurgitant orifice area (EROA) was calculated with the proximal isovelocity surface area 
(PISA) method.(16,17) In brief, the mitral valve was centered and zoomed at the apical 
3- or 4-chamber view and the Nyquist limit was lowered to a point where the proximal 
flow convergence region could be clearly visualized. PISA radius was then measured in 
a mid-systolic frame. Peak velocity and time velocity integral of the mitral regurgitant 
jet were measured on continuous wave Doppler recordings of the mitral flow.(16,17) 
Regurgitant volume was calculated as the product of the surface area of the hemisphere 
and the velocity of aliasing.(16,17) The EROA was calculated from the ratio of regurgitant 
flow to peak regurgitant velocity. Vena contracta was additionally measured according 
to recommendations.(16,17)
The underlying mechanism of MR was defined as predominantly functional (when 
leaflets were non-pathologic) or degenerative (based on mitral leaflet prolapse, leaflet 
and chordae thickening and mitral annulus calcification).(18) Improvement of MR de-
fined as reduction of the initial EROA by ≥30% (representing reduction by at least one 
grade) was evaluated before hospital discharge and at 12 months follow-up.(18)
SPSS software version 20 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. 
Based on visual inspection of the histograms the continuous variables were categorized 
as normally distributed, and presented as mean and standard deviation or standard error 
of the mean, or non-normally distributed, and presented as median and inter-quartile 
range. Categorical variables were presented as frequencies and percentages.
Linear mixed model analysis was used to assess changes in mitral regurgitant volume, 
EROA, vena contracta, aortic valve area, transaortic mean gradient, LVEF, LV mass, LVEDV 
and LVESV and the mean and standard error of the mean were presented. Time (pre-TAVI, 
pre-discharge and 12 months) was used as the main fixed effect. The overall changes of 
each tested variable from baseline to follow-up and also between each specific time 
point were evaluated. Main effects were compared with Bonferroni adjustment.
Additionally, patients were categorized according to improvement (by ≥30% reduc-
tion of baseline EROA) or non-improvement of MR (<30% reduction of baseline EROA) 
during follow-up. Continuous variables were compared with the unpaired Student’s 
t-test if they were normally distributed or the Mann-Whitney test otherwise. Categorical 
variables were compared with the χ2 test or Fisher’s exact test, as indicated. Binary logis-
tic regression analysis was used for the evaluation of the associates of MR improvement 
and estimated odds ratios and 95% confidence intervals were calculated. On multivari-
ate analysis only those variables with a p < 0.2 in the univariate model were included. A 
two-sided p < 0.05 was considered statistically significant.
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RESULTS
Table 1 and table 2 summarize the clinical and echocardiographic characteristics of the 
patients (mean age 82±6 years, male 41%). Patients had a mean logistic Euroscore I of 
27±15%. Overall 56 (95%) Edwards Sapien valves (14 of 23 mm, 41 of 26 mm and 1 of 29 
mm) and 3 (5%) CoreValve prostheses (2 of 26 mm, and 1 of 29 mm) were implanted. At 
baseline (pre-TAVI), mild MR was observed in 41 (70%) patients, moderate in 16 (27%), 
and severe in 2 (3%).
As expected, there was a significant overall increase in aortic valve area (from 
0.70±0.02 cm2 to pre-TAVI to 1.80±0.06 cm2 pre-discharge and to 1.69±0.07 cm2, 
p < 0.001 at 12 months follow-up), and reduction in transaortic mean gradient (from 
38.7±2.0 mmHg to 9.9±0.6 mmHg and to 11.3±0.9 mmHg, p < 0.001) from baseline to 
pre-discharge to 12 months, respectively. In addition, significant reductions in LV mass 
(from 234±8 gr to 229±8 gr and to 215±7 gr, p = 0.013) and LVESV (from 71.9±5.9 ml to 
68.6±5.3 ml and to 60.8±4.9 ml, p = 0.042) and an increase in LVEF (from 45.7±2.0% 
to 45.9±1.7% and to 50.5±1.5%, p = 0.015) were observed during the follow-up time. 
Changes in LVEF and LVESV were significant only between pre-discharge and 12 month 
Table 1. Baseline characteristics of patients
 N = 59
Age (years) 82±6
Male n (%) 24(41)
BSA (m2) 1.8±0.1
Creatinine (µmol/l) 95(76-156)
Diabetes mellitus n (%) 23(39)
Atrial fibrillation n (%) 17(29)
Peripheral vascular disease n (%) 29(49)
Smoking n (%) 22(37)
Coronary artery disease n (%) 42(71)
NYHA functional class III-IV n (%) 43(73)










 ACE-inhibitors / ARB-II 32(54)
Transfemoral / Transapical TAVI n (%) 24(41)/35(59)
Edwards Sapien / CoreValve n (%) 56(95)/3(5)
ACE, Angiotensin converting enzyme; ARB-II, Angiotensin II receptor blocker; BSA, Body surface area; NYHA, 
New York Heart Association; TAVI, transcatheter aortic valve implantation
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time points, indicating the occurrence of LV reverse remodeling at mid-term follow-up 
after TAVI (Table 3).
During the 12 months follow-up, there was an overall significant reduction in MR 
volume (from 35.6±2.2 ml to 18.0±1.8 ml and to 17.5±2.4 ml, p < 0.001), EROA (from 
20.5±1.1 mm2 to 13.9±1.2 mm2 and to 10.6±1.2 mm2, p < 0.001) and vena contracta (from 
5.0±0.15 mm to 3.8±0.18 mm and to 3.5±0.24 mm, p < 0.001) (Table 3). Notably, for all 
MR parameters, changes were only significant between baseline and pre-discharge 
echocardiogram but not between pre-discharge and 12 months follow-up.
Table 2. Baseline echocardiographic parameters
N = 59
Aortic valve area (cm2) 0.70±0.19
Mean transaortic gradient (mmHg) 39±16
Peak transaortic gradient (mmHg) 62±23
Left ventricular ejection fraction (%) 45±15
Left ventricular mass (gr) 234±67
Left ventricular end-diastolic volume (ml) 124 ±53
Left ventricular end-systolic volume (ml) 71±44
Systolic pulmonary arterial pressure (mmHg) 41±14
Left atrial volume index (ml/m2) 44±14
Functional mitral regurgitation n (%) 17(29)
Mitral regurgitant volume (ml/beat) 35.6±7.1
Mitral EROA (mm2) 20.5±8.4
Mitral vena contracta (mm) 5.0±1.2
EROA, Effective regurgitant orifice area
Table 3. Changes in mitral regurgitation, left ventricular dimensions and left ventricular function over a 12 
month period following TAVI
Pre-TAVI Pre-discharge 12-months Follow-up p-value *
Mitral regurgitant volume (ml) 35.6[2.2] 18.0 [1.8] † 17.5 [2.4] † <0.001
Mitral EROA (mm2) 20.5 [1.1] 13.9 [1.2]† 10.6 [1.2] † <0.001
Mitral vena contracta (mm) 5.0 [0.15] 3.8 [0.18] † 3.5 [0.24] † <0.001
AVA (cm2) 0.70 [0.02] 1.80 [0.06] † 1.69 [0.07] † <0.001
MG (mm Hg) 38.7 [2.0] 9.9 [0.6] † 11.3 [0.9] † <0.001
LVEF (%) 45.7 [2.0] 45.9 [1.7] 50.5 [1.5] † 0.015
LV mass 234 [8] 229 [8] 215 [7] † 0.013
LVEDV (ml) 124.4 [6.9] 118.6 [6.1] 114.4 [6.4] 0.118
LVESV (ml) 71.9 [5.9] 68.6 [5.3] 60.8 [4.9] † 0.042
* p-values are given for total change of the parameter over the total follow up time.
† p < 0.05 vs. re-TAVI value.All values are expressed as mean [standard error of the mean].
AVA, Aortic valve Area; EROA, Effective regurgitant orifice area; LV, Left ventricle; LVEDV, LV end-diastolic 
volume; LVEF, LV ejection fraction; LVESV, LV end-systolic volume; MG, Mean Gradient.
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Overall, MR improved by ≥30% reduction in EROA at pre-discharge in 35 (59%) patients 
whereas in 24(41%) EROA reduced by <30%, remained unchanged or worsened. At 12 
months follow-up MR improved by ≥30% reduction of baseline EROA in an additional 10 
(17%) patients in whom an acute post-TAVI improvement had not been observed. There 
were no differences between acute improvers and non-improvers in logistic Euroscore 
(26±16% vs. 28±15%, p = 0.737), baseline aortic valve area (0.70±0.18 cm2 vs. 0.70±0.20 
cm2, p = 0.946) or mean aortic valve gradient (38±17 mmHg vs. 39±13 mmHg, p = 0.781). 
LV volumes and LVEF similarly did not differ between groups (Table 4). However, pa-
tients with acute improvement in MR after TAVI had higher baseline EROA compared to 
non-improvers (22.8±8.8 mm2 vs. 17.3±7.5 mm2, p = 0.013). In addition, the proportion of 
predominantly functional MR was higher among the MR improvers than non-improvers 
(14 (40%) vs. 3 (12%), respectively; p = 0.022) (Table 4).






Age (years) 82±7 84±5 0.282
Male 13(37) 11(45) 0.504
Creatinine (µmol/l) 106(84-151) 90(69-124) 0.589
Diabetes 12(34) 11(45) 0.327
Atrial fibrillation 10(28) 7 (29) 0.960
Coronary artery disease 25(71) 17(70) 0.960
NYHA functional class III-IV 28(80) 15(62) 0.137
Logistic Euroscore I (%) 26±16 28±15 0.737
Transfemoral 16(45) 8(33) 0.342
Aortic valve area (cm2) 0.70±0.18 0.70±0.20 0.946
Mean transaortic gradient (mmHg) 38±17 39±13 0.781
Peak transaortic gradient (mmHg) 62±24 62±20 0.965
Left ventricular ejection fraction (%) 45±14 47±17 0.708
Left ventricular mass (gr) 232±65 237±72 0.808
Left ventricular end-diastolic volume (ml) 126±48 121±61 0.753
Left ventricular end-systolic volume (ml) 74±42 68±50 0.647
Systolic pulmonary arterial pressure (mmHg) 40±14 43±15 0.539
Left atrial volume index (ml/m2) 44±16 44±10 0.966
Mitral regurgitant volume (ml/beat) 37.5±17 32.8±17 0.305
Mitral EROA (mm2) 22.8±8.8 17.3±7.5 0.013
Mitral vena contracta (mm) 5.2±1.2 4.8±1.1 0.188
Functional mitral regurgitation 14(40) 3(12) 0.022
*p-values are given for the difference in baseline characteristics between patients with a reduction in ef-
fective regurgitant orifice area by ≥30% after TAVI (MR improvers) vs. patients with <30% reduction (MR 
non-improvers). EROA, Effective regurgitant orifice area; MR, Mitral regurgitation; NYHA: New York Heart 
Association.
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In the univariate analysis only baseline EROA (odds ratio 1.093, 95% confidence interval: 
1.015-1.177, p = 0.019) and functional MR (odds ratio 4.667, 95% confidence interval: 1.167-
18.659, p = 0.029) were associated with post-TAVI MR improvement. Both baseline mitral 
EROA (odds ratio 1.095, 95% confidence interval: 1.013-1.185, p = 0.023) and functional MR 
(odds ratio 4.714, 95% confidence interval: 1.105-20.112, p = 0.036) were independently 
related to post-TAVI MR improvement (Table 5).
dISCUSSION
The present evaluation showed that in patients with severe aortic stenosis and concomi-
tant mild or more MR who are treated with TAVI, a significant improvement in MR (defined 
by ≥30% reduction of baseline EROA) occurs in 59% of patients immediately after TAVI and 
in an additional 17% at 12 months follow-up. In addition, significant reductions in LV vol-
umes and improvement in LVEF were observed at 12 months follow-up. Baseline EROA and 
predominantly functional MR were independently associated with acute improvement in 
MR. These findings indicate that the acute improvement in MR is driven by a significant 
reduction in LV pressure afterload and in systolic left-atrium-LV pressure gradient whereas 
the MR improvement at mid-term follow-up may be associated with LV reverse remodeling.
Table 5. Correlates of postoperative reduction in EROA area by ≥30% of baseline EROA following TAVI
Variables Univariate analysis Multivariate analysis
OR (95% CI) p-value OR (95% CI) p-value
Age (years) 0.955 (0.897-1.038) 0.280
Male 0.698 (0.678-2.007) 0.231
Creatinine (µmol/l) 0.997 (0.989-1.004) 0.343
Diabetes 0.617 (0.213-1.787) 0.373
Atrial fibrillation 0.971 (0.309-3.055) 0.960
Coronary artery disease 0.960 (0.327-3.237) 0.961
Aortic valve area (cm2) 0.907 (0.058-14.616) 0.907
Mean transaortic gradient (mmHg) 0.995 (0.963-1.029) 0.777
Left ventricular ejection fraction (%) 0.993 (0.960-1.028) 0.703
Left ventricular mass (gr) 0.999 (0.991-1.007) 0.804
Left ventricular end-diastolic volume (ml) 1.002 (0.992-1.012) 0.748
Left ventricular end-systolic volume (ml) 1.003 (0.991-1.014) 0.668
Systolic pulmonary pressure (mmHg) 0.988 (0.953-1.025) 0.532
Left atrial volume indexed (ml/m2) 0.999 (0.963-1.037) 0.965
Mitral EROA (mm2) 1.093 (1.015-1.177) 0.019 1.095 (1.013-1.185) 0.023
Functional mitral regurgitation 4.667 (1.167-18.659) 0.029 4.714 (1.105-20.112) 0.036
CI, confidence interval; EROA, Effective regurgitant orifice area; OR, odds ratio
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Although patients with significant MR were generally excluded from early TAVI stud-
ies, data from registries report a prevalence of 1-9% of severe MR among TAVI recipients 
while the percentage of patients with at least moderate MR ranges between 24-48%.
(1-3,5) Differences in reported MR prevalence may be related to a non-standardized as-
sessment of MR grade. Only a few series have used quantitative measurements of MR 
severity in patients undergoing TAVI.(6,7) For example, Giordana et al reported a mean 
EROA of 24.4±11.5 mm2 in 35 patients treated with TAVI.(6) In addition, data from the 
TRanscatheter EndoVascular Implantation of VALves (REVIVAL) II trial showed that 63% 
of patients had at least mild-moderate MR with a mean vena contracta width of 0.5±0.2 
cm.(7) Quantification of MR prior to aortic valve replacement is relevant since the pres-
ence of more than moderate MR may indicate a double valve replacement.(9) However, 
several series have shown that MR may improve after aortic valve replacement, which 
coincides with better long-term outcome.(4,19)
Quantitative evaluation of changes in MR and timing of these changes are also im-
portant for decision making of patients with severe aortic stenosis. The present study 
showed that the majority of patients improved by ≥30% reduction in EROA immediately 
after TAVI and only one-fifth improve later at follow-up in parallel with timing of mani-
fest LV reverse remodeling. The Placement of Aortic Transcatheter Valve (PARTNER) trial 
cohort A showed an improvement by ≥1 grade at 30 days in 57.7% of patients with at 
least moderate MR at baseline who were treated with TAVI.(19) However, the prevalence 
of moderate and severe MR remained unchanged at 1 year follow-up (17% at 30 days vs 
19.9% at 1 year).(20) Of note, for overall patients allocated to the TAVI arm, there was a 
significant reduction in MR grade at 2 years follow-up (from 1.94 ± 0.78 at baseline to 
1.65 ± 0.84 at discharge and 1.67 ± 0.81 at 2 years; p = 0.03) together with reductions in 
LVESV (from 57.9 ± 35.1 ml at baseline to 52.8 ± 30.9 ml at discharge and 50.9 ± 29.5 ml 
at 2 years, p = 0.04) and improvement in LVEF (from 53.4 ± 12.6% at baseline to 53.8 ± 
12.1% at discharge and 57.4 ± 10.4% at 2 years, p < 0.001).(20) These results confirm our 
findings and indicate that there is a significant reduction in MR acutely, probably due 
to reductions in LV pressure overload and pressure between left atrium and LV, and a 
further improvement at mid- and long-term follow-up related most likely to changes in 
LV volumes and improvement in LVEF. However, it remains unclear how to identify the 
patients who will show an improvement in MR after aortic valve replacement and the 
patients who may benefit from double valve replacement.
Several studies have evaluated the determinants of improvement in MR after aortic 
valve replacement.(21-28) The largest evidence is based on surgical aortic valve re-
placement trials. The results are disparate, probably due to different methodologies 
to quantify MR severity and heterogeneous populations. However, a few factors are 
frequently observed: functional MR and MR grade at baseline are associated with 
improvement in MR after aortic valve replacement.(22-26) In patients undergoing TAVI, 
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few studies have investigated the associates of improvement in MR after TAVI.(1,2,4,9) 
For example, Toggweiler et al showed that the presence of functional MR was associ-
ated with increased probability of improvement in MR at 1 year follow-up after TAVI.
(1) Similarly, data from the Italian registry showed that independent associates of MR 
improvement after TAVI were functional etiology of MR (OR 2.6, p = 0.005), absence of 
atrial fibrillation (OR 2.02, p = 0.003) and absence of pulmonary hypertension (OR 2.9 
p = 0.002).(4) From the PARTNER trial cohort A, LV end-diastolic diameter was a univari-
ate associate of improvement in MR (OR 5.42, p = 0.02).(19) However, independent fac-
tors associated with MR improvement were not observed. Similarly, the present study 
showed that functional MR and larger baseline EROA were independently associated 
with improvement in MR after TAVI. In contrast to organic etiology of MR, functional MR 
may respond to an acute reduction in LV pressure overload. Reduction in EROA to de-
fine improvement in MR is a rather strong parameter, since EROA is less load dependent 
than other parameters such as regurgitant volume or color flow mapping. A reduction 
in ≥30% of baseline EROA may only be observed in patients with a large baseline EROA. 
Therefore, it is not surprising that this parameter is independently associated with MR 
improvement.
There are some notable clinical implications of this evaluation. Reduction in MR after 
TAVI is occurring mainly at pre-hospital discharge and there may not be a reason for 
delaying an additional intervention when MR persists after TAVI. In addition, patients 
with significant MR may not be excluded from TAVI, especially if the underlying MR 
pathology is functional. On the other hand, for TAVI candidates with significant MR of 
predominantly degenerative pathology, surgical aortic valve replacement or staged 
transcatheter mitral valve repair may be considered.
Several limitations of this study should be acknowledged. The study was retrospective 
and performed in a single center. The number of patients with severe MR at baseline 
was relatively low. Moreover, for the initial inclusion of patients a semi-quantitative ap-
proach of MR grading was performed. The follow-up echocardiogram was available only 
for 44 of the 59 initially included patients. Finally, only 3 patients with CoreValve system 
were included and the influence of the type of prosthesis in postoperative MR cannot 
be appraised.
CONCLUSION
In patients with more than mild MR undergoing TAVI there is a significant MR reduction 
in the acute post-operative phase in almost two-thirds of patients. However, an addi-
tional 17% of patients may show a later mid-term improvement. Baseline mitral EROA 
and predominately functional MR are independently related to acute MR improvement.
108 Chapter 7
dISCLOSURES
VD received consulting fees from St. Jude Medical and Medtronic. The Department of 
Cardiology in Leiden received grants from, St. Jude Medical, Medtronic, Boston Scientific 
Corporation, Biotronik, Sadra Lotus, and GE Healthcare. SK is financially supported by a 
grant from the Hellenic Cardiology Society, VK and PD are supported by a grant from 
European Society of Cardiology.
Quantitative analysis of changes in mitral regurgitation after transcatheter aortic valve implantation 109
REFERENCES
 1. Toggweiler S, Boone RH, Rodes-Cabau J, et al. Transcatheter aortic valve replacement: Outcomes 
of patients with moderate or severe mitral regurgitation. J Am Coll Cardiol 2012; 59: 2068-2074
 2. Hekimian G, Detaint D, Messika-Zeitoun D, et al. Mitral regurgitation in patients referred for 
transcatheter aortic valve implantation using the edwards sapien prosthesis: Mechanisms and 
early postprocedural changes. J Am Soc Echocardiogr 2012; 25: 160-165
 3. Tzikas A, Piazza N, van Dalen BM, et al. Changes in mitral regurgitation after transcatheter aortic 
valve implantation. Catheter Cardiovasc Interv 2010; 75: 43-49
 4. Bedogni F, Latib A, De Marco F, Agnifili M, Oreglia J, Pizzocri S, Latini RA, Lanotte S, Petronio AS, 
De Carlo M, Ettori F, Fiorina C, Poli A, Cirri S, De Servi S, Ramondo A, Tarantini G, Marzocchi A, 
Fiorilli R, Klugmann S, Ussia GP, Tamburino C, Maisano F, Brambilla N, Colombo A, Testa L. Interplay 
between mitral regurgitation and transcatheter aortic valve replacement with the corevalve 
revalving system: A multicenter registry. Circulation. 2013; 128: 2145-2153
 5. D’Onofrio A, Gasparetto V, Napodano M, et al. Impact of preoperative mitral valve regurgitation 
on outcomes after transcatheter aortic valve implantation. Eur J Cardiothorac Surg 2012; 41: 1271-
1276
 6. Giordana F, Capriolo M, Frea S, et al. Impact of tavi on mitral regurgitation: A prospective echocar-
diographic study. Echocardiography. 2013; 30: 250-257
 7. Durst R, Avelar E, McCarty D, et al. Outcome and improvement predictors of mitral regurgitation 
after transcatheter aortic valve implantation. J Heart Valve Dis 2011; 20: 272-281
 8. Maleszka A, Kleikamp G, Zittermann A, et al. Simultaneous aortic and mitral valve replacement in 
octogenarians: A viable option? Ann Thorac Surg 2008; 86: 1804-1808
 9. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease 
(version 2012). Eur Heart J 2012; 33: 2451-2496
 10. Barbanti M, Ussia GP, Tamburino C. Percutaneous treatment of aortic stenosis and mitral regur-
gitation in the same patient: First human cases description. Catheter Cardiovasc Interv 2011; 78: 
650-655
 11. Kische S, D’Ancona G, Paranskaya L, et al. Staged total percutaneous treatment of aortic valve 
pathology and mitral regurgitation: Institutional experience. Catheter Cardiovasc Interv 2013; 82: 
552-63
 12. Ewe SH, Delgado V, Ng AC, et al. Outcomes after transcatheter aortic valve implantation: Trans-
femoral versus transapical approach. Ann Thorac Surg 2011; 92: 1244-1251
 13. Rodes-Cabau J, Dumont E, De LaRochelliere R, et al. Feasibility and initial results of percutane-
ous aortic valve implantation including selection of the transfemoral or transapical approach in 
patients with severe aortic stenosis. Am J Cardiol 2008; 102: 1240-1246
 14. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report 
from the american society of echocardiography’s guidelines and standards committee and the 
chamber quantification writing group, developed in conjunction with the european association 
of echocardiography, a branch of the european society of cardiology. J Am Soc Echocardiogr 
2005; 18: 1440-1463
 15. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right 
heart in adults: A report from the american society of echocardiography endorsed by the euro-
pean association of echocardiography, a registered branch of the european society of cardiology, 
and the canadian society of echocardiography. J Am Soc Echocardiogr 2010; 23: 685-713
110 Chapter 7
 16. Lancellotti P, Moura L, Pierard LA, et al. European association of echocardiography recommen-
dations for the assessment of valvular regurgitation. Part 2: Mitral and tricuspid regurgitation 
(native valve disease). Eur J Echocardiogr 2010; 11: 307-332
 17. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity 
of native valvular regurgitation with two-dimensional and doppler echocardiography. J Am Soc 
Echocardiogr 2003; 16: 777-802
 18. Unger P, Dedobbeleer C, Van Camp G et al. Mitral regurgitation in patients with aortic stenosis 
undergoing valve replacement. Heart 2010; 96: 9-14
 19. Barbanti M, Webb JG, Hahn RT, et al. Impact of preoperative moderate/severe mitral regurgitation 
on 2-year outcome after transcatheter and surgical aortic valve replacement: Insight from the 
partner (placement of aortic transcatheter valve) trial cohort a. Circulation 2013; 128: 2776-84
 20. Hahn RT, Pibarot P, Stewart WJ, et al. Comparison of transcatheter and surgical aortic valve 
replacement in severe aortic stenosis: A longitudinal study of echocardiography parameters in 
cohort a of the partner trial (placement of aortic transcatheter valves). J Am Coll Cardiol 2013; 61: 
2514-2521
 21. Ruel M, Kapila V, Price J, et al. Natural history and predictors of outcome in patients with concomi-
tant functional mitral regurgitation at the time of aortic valve replacement. Circulation 2006; 114: 
I541-546
 22. Barreiro CJ, Patel ND, Fitton TP, et al. Aortic valve replacement and concomitant mitral valve 
regurgitation in the elderly: Impact on survival and functional outcome. Circulation 2005; 112: 
I443-447
 23. Tunick PA, Gindea A, Kronzon I. Effect of aortic valve replacement for aortic stenosis on severity of 
mitral regurgitation. Am J Cardiol 1990; 65: 1219-1221
 24. Vanden Eynden F, Bouchard D, El-Hamamsy I, et al. Effect of aortic valve replacement for aortic 
stenosis on severity of mitral regurgitation. Ann Thorac Surg. 2007; 83: 1279-1284
 25. Waisbren EC, Stevens LM, Avery EG, et al. Changes in mitral regurgitation after replacement of the 
stenotic aortic valve. Ann Thorac Surg 2008; 86: 56-62
 26. Unger P, Plein D, Van Camp G, et al. Effects of valve replacement for aortic stenosis on mitral 
regurgitation. Am J Cardiol 2008; 102: 1378-1382
 27. Harris KM, Malenka DJ, Haney MF, et al. Improvement in mitral regurgitation after aortic valve 
replacement. Am J Cardiol 1997; 80: 741-745
 28. Brasch AV, Khan SS, DeRobertis MA, et al. Change in mitral regurgitation severity after aortic valve 
replacement for aortic stenosis. Am J Cardiol 2000; 85: 1271-1274
Chapter 8
Fate of transcatheter valve-in-valve 
implantation and redo cardiac surgery 
for failing bioprosthetic valves in patients 
with high operative risk
Spyridon Katsanos, Philippe J van Rosendael, 
Olivier W van den Brink, Philippe Debonnaire, Emer Joyce, Frank van der Kley, 




Objectives: The aim of the present evaluation was to compare the clinical outcome of 
patients with failing cardiac bioprostheses or mitral valve annuloplasty treated with 
transcatheter valve-in-valve with patients who underwent redo cardiac surgery.back-
ground: Transcatheter valve-in-valve implantation is a feasible treatment for patients 
with failing degenerated cardiac bioprostheses with increased operative risk, however 
the outcome of this therapy has not been compared with redo cardiac surgery. Meth-
ods: The long-term survival of 16 patients (age 80±2. 25% male) undergoing transcath-
eter valve-in-valve procedure was compared with that of 16 high-operative risk patients 
(age 70±1, 50% male) undergoing redo valve surgery. Results: Both groups of patients 
were comparable in terms of preoperative risk (logistic Euroscore I: 34.1±14.6% in pa-
tients treated with valve-in-valve vs. 30.8±20.3% in patients treated with redo surgery 
p = 0.605), functional status (New York Heart Association class ≥III: 9 (56%) in patients 
treated with valve-in-valve vs. 7(44%) in patients treated with redo surgery, p = 1.000) 
and left ventricular ejection fraction (37% (27-52) in patients treated with valve-in-valve 
vs. 40% (26-57) in patients treated with redo surgery, p = 0.724). After a median follow-
up of 21 months (interquartile range 7-44), 10 (30%) patients died. Survival for patients 
treated with valve-in-valve did not differ from that of patients treated with redo cardiac 
surgery (log-rank p = 0.939).Conclusions: Patients with failing cardiac bioprostheses 
and high operative risk treated with transcatheter valve-in-valve have similar survival 
compared with patients undergoing redo cardiac surgery.
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INTROdUCTION
Structural valve deterioration is one of the main complications associated with bio-
prosthetic heart valves. Landmark randomized trials have shown a greater incidence 
of prosthetic heart valve failure among patients aged <65 years receiving aortic or 
mitral bioprostheses as compared with recipients of a mechanical prosthesis.(1-2) The 
incidence of structural valve deterioration declines significantly among patients older 
than 65 years. In large registries including more than 300, 000 patients undergoing aortic 
valve replacement the reoperation rate for patients receiving a bioprosthesis was 3.1% at 
11-13 years of follow-up compared with 2.3% reoperation rate for recipients of an aortic 
mechanical prosthesis.(3) However, the lower reoperation rates of mechanical valve pros-
theses are counterbalanced by an increased risk of bleeding complications associated 
with the lifelong use of anticoagulation.(1-3) This has resulted in a significant increase 
of bioprostheses over the last decades (from 18% in 1991 to 59% in 2003), mainly among 
older patients with associated comorbidities.(3) These patients who may present at 
follow-up with failing degenerated bioprostheses have an increased risk for reoperation.
The development of transcatheter aortic valve devices and the promising results 
of transcatheter aortic valve implantation in patients with high operative risk or who 
are deemed inoperable, has led to the off-label use of these devices in other high risk 
subgroups such as patients with failing degenerated cardiac bioprostheses.(4-6) Dvir et 
al have recently reported the outcomes of 202 patients with failing aortic bioprostheses 
who underwent transcatheter valve-in-valve implantation, the largest series described 
so far. (4) The procedural success rate was 93.1% and the 1-year survival (based on 
data available from 85 patients) was almost 86%. (4) However, the results of this series 
concerned only patients with failing degenerated aortic bioprostheses and were not 
compared with a control group of patients undergoing redo cardiac valve surgery. The 
outcome of transcatheter valve-in-valve implantation in positions other than aortic (mi-
tral or tricuspid) or in failing mitral annuloplasty was not evaluated. Accordingly, the aim 
of the present evaluation was to compare the clinical outcome of patients with failing 
cardiac bioprostheses or mitral valve annuloplasty treated with transcatheter valve-in-
valve with high risk patients who underwent redo cardiac surgery.
MATERIALS ANd METHOdS
The present evaluation included patients who underwent elective transcatheter valve-
in-valve procedures or redo cardiac surgery for failing aortic or mitral bioprostheses 
or failing mitral valve annuloplasty. From February 2008, transcatheter valve-in-valve 
has been a therapeutic alternative to cardiac surgery at our institution for patients with 
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failing degenerated aortic or mitral bioprostheses and very high operative risk or contra-
indications for surgery. In addition, from 2010 this therapy was extended to patients with 
failing mitral valve annuloplasty and contraindications for surgery. All patients provided 
informed consent for the procedures. The clinical and echocardiographic data of this 
population were prospectively collected in the departmental Cardiology Information 
System (EPD-Vision®, Leiden University Medical Centre) and retrospectively analysed.
Furthermore, a retrospective search in the echocardiographic database was performed 
to identify patients who underwent elective redo cardiac surgery for failing mitral and 
aortic (biological or mechanical) prostheses and failing mitral valve annuloplasty. Pa-
tients with active endocarditis were excluded. The clinical characteristics and logistic 
Euroscore I in this group were reviewed to further select a similar comparator group of 
patients treated with transcatheter valve-in-valve.
The long-term outcome of patients undergoing transcatheter valve-in-valve and 
patients undergoing redo cardiac surgery were compared. All cause-mortality was the 
primary endpoint. The institutional review board approved the retrospective analysis of 
clinically acquired data and waived the need for patient written informed consent.
Clinical and echocardiographic data
Clinical data, including demographics, comorbidities, logistic Euroscore I and medica-
tions were recorded. All patients underwent transthoracic and transesophageal echo-
cardiography prior to the procedures. Left ventricular (LV) end-diastolic (LVEDV) and 
end-systolic volumes (LVESV) were measured using the Simpson method and LV ejection 
fraction (LVEF) was derived.(7) Type of valvular prosthesis dysfunction (regurgitation or 
stenosis) and its severity were evaluated according to current recommendations.(8)
Transcatheter valve-in-valve procedure
Transcatheter valve-in-valve procedures were performed at the hybrid operating room, 
under general anesthesia and with fluoroscopy and transesophageal echocardiogra-
phy guidance. Edwards Sapien or Sapien XT valves were implanted in aortic or mitral 
positions through a transapical approach to allow a proper coaxial alignment of the 
transcatheter valve within the prosthetic valve [5]. For valve-in-ring procedures, the 
transcatheter valve was positioned at the center of the mitral valve with 50% of the 
frame in the left atrium and 50% in the left ventricle.(9)
Follow-up
Following one month after the procedure a repeat comprehensive echocardiographic 
study was performed for patients treated with transcatheter valve-in-valve. LVEDV, 
LVESV and LVEF and the hemodynamics of the valve were assessed. (7-8) In addition, 
patients were prospectively followed-up for all-cause mortality.
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For patients treated with redo cardiac surgery, data on all-cause mortality was col-
lected by retrospective review of medical records and retrieval of survival status through 
the municipal civil registries.
Statistical analysis
A package of SPSS software version 20, (SPSS Inc., Chicago, IL, USA) was used for statisti-
cal analyses. The Gaussian distribution of continuous variables was checked with the 
Kolmogorov-Smirnov test. If normally distributed, continuous variables were presented 
as mean and standard deviation. Otherwise, median and interquartile range was pro-
vided. Categorical variables were presented as number and frequencies. The Student’s 
t-test or Mann-Whitney test were used to compare continuous variables normally or 
non-normally distributed, respectively. Categorical variables were compared with the χ2 
test or Fisher’s exact test, as appropriate. Patients were dichotomized according to treat-
ment with redo cardiac surgery or transcatheter valve-in-valve procedure. Cumulative 
events rates were calculated using the Kaplan-Meier method and were then compared 
across groups with the log-rank test.
RESULTS
Preoperative clinical and echocardiography characteristics
The population consisted of 32 patients with failing mitral or aortic prostheses or fail-
ing mitral valve annuloplasty: 16 patients treated with transcatheter valve-in-valve 
procedure between September 2008 and April 2012 (Table 1) and 16 who underwent 
redo cardiac surgery between June 2000 and February 2008 (Table 2). In the group of pa-
tients undergoing transcatheter valve-in-valve, the mechanism of prosthesis failure was 
severe aortic stenosis in 7 patients, severe aortic regurgitation in 3, and combined aortic 
stenosis and regurgitation in 2. The remaining 4 patients had severe mitral regurgita-
tion. In the group of patients who underwent redo cardiac valve surgery, aortic stenosis 
was observed in 4 patients, aortic regurgitation in 7 and combined aortic stenosis and 
regurgitation in 4. Moreover, one patient had combined stenosis and regurgitation of 
the degenerative aortic bioprosthesis and severe regurgitation of the native mitral valve 
and was treated with surgical replacement of both valves.
Table 3 summarizes the baseline characteristics of the overall population and 
both groups of patients. Patients treated with transcatheter valve-in-valve were sig-
nificantly older than patients treated with redo cardiac surgery (80±2 vs. 70±1 years, 
respectively; p = 0.001). However, there were no differences in logistic Euroscore I or 
comorbidities, such as diabetes, renal dysfunction, and clinical symptoms (Table 3). 
Additionally, LVEF was comparable in both groups (37(27-52)% in patients treated 
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with transcatheter valve-in-valve vs. 40 (26-57)% in patients undergoing redo cardiac 
surgery, p = 0.724).
Echocardiographic follow-up of patients undergoing transcatheter valve-in-
valve procedures
In the group of patients undergoing transcatheter valve-in-valve in aortic position, LVEF 
increased at 1 month follow-up (37% (28-48) vs. 40% (26-53), p = 0.014) and the peak 
and mean transvalvular gradients were 30.5 (23.7-45.5) mmHg and 16 (10.2-20) mmHg, 
respectively. Severe intra-valvular regurgitation immediately after deployment of the 
transcatheter valve into the prosthetic aortic valve requiring emergent repeat transcath-
eter valve-in-valve was recorded in one patient.(10) Mild paravalvular regurgitation was 
observed in 1 (10%) patient at follow-up. In patients treated with transcatheter valve-in-
Table 1. Brief history of patients undergoing transcatheter valve-in-valve procedures
Patient 
no






1 AVR (Medronic Freestyle stentless 21 mm) AS 62 16.45 AV Edwards Sapien 23 mm
2 AVR (Carpentier Edwards bioprosthesis 
21 mm) + MVP
AS 78 17.05 AV Edwards Sapien 23 mm
3 AVR (Medronic Freestyle 23 mm) AR 84 18.06 AV Edwards Sapien 26 mm
4 AVR (Medronic Freestyle 23 mm) AS 85 24.69 AV Edwards Sapien 23 mm
5 AVR + MVP (Edwards annuloplasty ring 
28 mm) + CABG
MR 74 25.58 MV Edwards Sapien 26 mm
6 AVR (Carpentier Edwards 23 mm) AS 77 26.29 AV Edwards Sapien 23 mm
7 AVR (Carpentier Edwards 21 mm) + CABG AS 89 29.97 AV Edwards Sapien 23 mm
8 AVR (Carpentier Edwards Perimount 
bioprosthesis 23 mm) + MVP + TVP + 
GABG
AS 83 30.38 AV Edwards Sapien 23 mm
9 AVR (Medronic Mosaic bioprosthesis 
23 mm) + CABG + MVP + TVP
AS 72 31.39 AV Edwards Sapien 23 mm
10 MVR (Medronic Intact bioproshesis 
27 mm)
MR 82 33.24 MV Edwards Sapien 26 mm
11 AVR + MVR (Medronic Mosaic 
bioprosthesis 27 mm)
MR 79 41.83 MV Edwards Sapien 26 mm
12 AVR (Carpentier Edwards 25 mm) + CABG AR 91 51.44 AV Edwards Sapien 26 mm
13 AVR (Medronic Freestyle 23 mm) + CAGB AR 82 52.61 AV Edwards Sapien 26 mm
14 AVR (Medronic Intact 25 mm) + CABG AS+AR 83 58.39 AV Edwards Sapien 26 mm
15 AVR (Medronic Freestyle 23 mm) AS+AR 81 61.78 AV Edwards Sapien 26 mm
16 MVP (Edwards annuloplasty ring 28 mm) 
+ TVP
MR 81 27.62 MV Edwards Sapien 26 mm
Data are expressed as number, AS, aortic stenosis; AR, aortic regurgitation; AVR, aortic valve replacement; 
CABG, Coronary artery bypass grafting, MR, mitral regurgitation; MVP, Mitral valve repair; MVR, Mitral valve 
replacement; TVP, tricuspid valve annuloplasty
Fate of transcatheter valve-in-valve implantation and redo cardiac surgery for failing bioprosthetic valves 117
valve for failing mitral valve bioprosthesis the peak and mean transvalvular gradients at 
1 month follow-up were 13.4 mmHg and 5 mmHg, respectively. Finally, only one of the 
2 patients treated with transcatheter valve-in-ring survived at 1 month follow-up and 
underwent repeat echocardiography. The peak and mean transvalvular gradient were 17 
and 6.5 mmHg, respectively.
Table 2. Brief history of patients undergoing redo cardiac surgery
Patient 
no





17 AVR(Medtronic Intact 23 mm) AS+AR 81 83.75 AVR(Edwards Lifesciences 23 
mm) + CABG
18 AVR (Medtronic Hall 29 mm) AR 62 13.77 AVR (St. Jude Medical 29 mm)
19 MVR (Medronic Intact bioproshesis 
33 mm)
AR 76 17.87 AVR (Edwards pericardial 23 mm) 
+ MVP
20 AVR (NA) AR 65 20.19 AVR (Medtronic Freestyle 29 mm)
21 AVR (Carpentier Edwards 23 mm) AS 81 20.33 AVR(Hancock II porcine 
Medtronic 23 mm) + MVR 
(Edwards 29 mm)
22 AVR(Medtronic Freestyle 27 mm) AS+AR 59 22.64 AVR (St. Jude Medical 29 mm)
23 MVR (Carbomedics 29 mm) AS 71 24.68 AVR (Carbomedics 21 mm) + 
MVP+TVP
24 AVR (St. Jude Medical 25 mm) AR 65 35.72 AVR (Carpentier-Edwards 
Perimount magna 25 mm) + 
CAGB
25 AVR (Medronic Hall Mechanical 23 
mm)
AS+AR 69 35.80 AVR (Carpentier-Edwards 
Perimount 23 mm)
26 AVR (Medronic Mosaic ultra 27 mm) AR 71 14.67 AVR (Medronic Mosaic ultra 27 
mm)




66 23.07 AVR (St. Jude Medical 23 mm) + 
MVR (St. Jude Medical 31 mm) 
+ CABG
28 AVR (Bjork-Shilley 25 mm) AR 52 69.11 AVR (St. Jude Toronto stentless 
29 mm) + Hemashield 
prosthesis32 mm
29 AVR (Carbomedics 25 mm) AR 68 46.49 AVR (Medtronic Freestyle 29 mm) 
+ MVP + TVP
30 AVR (Medronic Mosaic 19 mm) AS 76 16.03 AVR (Medtronic Freestyle 23 mm)
31 AVR (Medronic Intact 25 mm) AS 84 23.42 AVR (Edwards Perimount Magna 
23 mm)
32 AVR (Medtronic Freestyle 27 mm) AS+AR 76 33.14 AVR (Edwards Perimount Magna 
25 mm)
Data are expressed as number, AS, aortic stenosis; AR, aortic regurgitation; AVR, aortic valve replacement; 
CABG, Coronary artery bypass grafting; MR, mitral regurgitation; MVP, Mitral valve repair; MVR, Mitral valve 
replacement; TVP, tricuspid valve annuloplasty.
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Age (years) 75±9 70±1 80±2 0.001
Male, n (%) 12(38%) 8(50%) 4(25%) 0.273
Diabetes, n (%) 3 (13%) 1(6%) 3(19%) 0.600
Creatinine (µmol/L) 94 (73-140) 94 (73-167) 94 (67-140) 0.879
Coronary artery disease, n (%) 14 (44%) 4(25%) 10(63%) 0.073
NYHA functional class III-IV, n (%) 15 (47%) 7(44%) 8(50%) 1.000






















Logistic Euroscore I 32.5±17.5 30.8±20.3 34.1±14.6 0.605
Left ventricular ejection fraction (%) 38(27-55) 40(26-57) 37(27-52) 0.724
Years since previous cardiac surgery 9±5 9±6 9±4 0.696
Number of previous cardiac surgeries 1(1-2) 1(1-1) 1(1-3) 0.423
Data are expressed as n (%), mean ± SD and median (interquartile range), ACE, Angiotensin converting 
enzyme; NYHA, New York Heart Association. p Value (REDO surgery vs Valve-in-Valve)
Figure 1. Kaplan-Meier method for comparison between patients treated with surgical redo or transcath-
eter valve-in-valve with Edwards Sapien valve for failing bioprosthetic valves.
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Outcomes
In the group treated with transcatheter valve-in-valve, 2 patients died before hospital dis-
charge (in-hospital mortality 12%) whereas in the surgically treated group there were no 
in-hospital deaths. During a median follow-up of 21 (7-41) months, 10 (30%) patients died. 
Cumulative survival at 12 and 24 months for the group of patients treated with valve-in-
valve procedure were 75% and 75%, respectively, whereas for the redo cardiac surgery 
group the survival rates were 72% and 72%, respectively (log-rank, p = 0.939) (Figure 1).
dISCUSSION
The present single center experience shows that the long-term survival of patients with 
failing bioprosthetic valves and high operative risk who underwent transcatheter valve-
in-valve implantation is similar to that of high risk patients who were treated with redo 
cardiac surgery.
The choice of a mechanical or a biological prosthesis is mainly determined by the 
risks associated with lifelong anticoagulant treatment for mechanical prostheses (bleed-
ing and thromboembolism) and the risk of structural valve degeneration of biological 
prostheses. These risks are strongly associated with age and comorbidities of the pa-
tients and valve position (mitral vs. aortic). In the Veterans Affairs trial, randomizing 575 
patients to mechanical or biological prosthesis in aortic or mitral positions, an increased 
structural deterioration of bioprosthetic valves was observed only for patients younger 
than 65 years.(1) In addition, the Edinburgh Heart Valve trial, randomizing 541 patients to 
mechanical prosthesis (Bjork-Shiley) or porcine prostheses (Hancock or Carpentier-Ed-
wards), reported a lower 20-year reoperation rate among patients receiving a mechani-
cal prosthesis than recipients of a porcine prosthesis (2.5% vs. 5%, p < 0.001).(2) However, 
the differences were more pronounced after 8-10 years for mitral valve prostheses and 
after 12-14 years for aortic valve prostheses. Therefore, current guidelines recommend 
the use of bioprosthetic valves only for patients ≥65 years of age.(11) At the same time, 
real life evidence shows that bioprosthetic valves are gradually prevailing over mechani-
cal valves, given the avoidance of need for anticoagulation and its associated lifetime 
bleeding risk.(11-12) A more recent observational study including more than 300,000 
patients older than 65 years undergoing aortic valve replacement confirmed the in-
creased risk of reoperation associated with the use of bioprostheses.(3) However, the 
study reported an increase in the use of bioprostheses over time (from 18% in 1991 to 
59% in 2003). Interestingly, patients receiving an aortic bioprosthesis were more likely to 
have associated comorbidities such as diabetes, chronic heart failure, renal dysfunction, 
cerebrovascular disease and chronic obstructive pulmonary disease that contribute to 
an increased surgical risk of a redo cardiac surgery in the future.(3,13-16)
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In recent years, the number of transcatheter valve-in-valve procedures has increased 
considerably. Reports from pioneer centers have shown acceptable inhospital survival 
for patients with failing bioprosthetic valves treated with transcatheter valve-in-valve 
procedures.(5,17-21) Still, most reports include small numbers of patients with lim-
ited follow-up time and concern almost exclusively degenerated aortic bioprostheses. 
Recently, the Global valve-in-valve registry of 202 patients showed that the 30-day-
mortality (8.4%) and one year survival (85.8%) of patients treated with valve-in-valve 
procedure did not differ significantly from survival observed in large transcatheter aortic 
valve implantation trials. (22) However, this registry included exclusively patients with 
failing bioprosthetic aortic valves and did not include a control group of patients treated 
with redo cardiac surgery.
The present study includes patients with both failing aortic and mitral bioprosthetic 
valves and additionally attempts to compare their long-term survival with a group of 
patients with similar preoperative risk that were treated surgically. Logistic Euroscore 
I was similar between groups. Patient groups were also comparable for other clinical 
characteristics that determine the outcome of redo cardiac valve surgery such as elective 
surgery, (13) renal dysfunction, (23) New York Heart Association functional class (13,15,16) 
and LVEF. (13,14) Survival after transcatheter valve-in-valve procedure was comparable to 
that of redo cardiac surgery suggesting that this technique could be an alternative for 
high risk patients in need of bioprosthesis valve replacement.
Transcatheter valve-in-valve offers many advantages compared to cardiac surgery. It 
is minimally invasive and technically simpler because sternotomy and cardiopulmonary 
bypass are not required. The increased awareness of this option alongside further studies 
demonstrating its feasibility will likely lead to growing numbers of patient referrals for 
transcatheter valve-in-valve procedures in the near future. Specifically, elderly patients 
at very high surgical risk who may have been previously deemed inoperable will have 
a potential alternative and viable option. Moreover the increasing use of bioprosthetic 
over mechanical valves that has already been observed in larger registries may be fur-
ther extended.(12) Finally, in everyday practice, it will be important for surgeons to use 
larger aortic bioprostheses and adapt their surgical technique in order to make a valve-
in-valve reoperation more feasible. (6)
LIMITATIONS
There are some limitations of this study. This is a report from a single center, with a small 
number of patients that are not matched one by one for preoperative risk parameters. 
Moreover the follow-up of the redo surgical group was assessed retrospectively. These 
results need to be confirmed in larger series of patients and possibly in randomized trials.
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CONCLUSIONS
This study indicates that high risk patients with degenerated bioprosthetic valves treated 
with transcatheter valve-in-valve implantation have similar long term survival with an 
analogous group treated with redo cardiac valve surgery. Therefore, transcatheter valve-
in-valve is a feasible alternative for high risk patients with degenerated bioprosthetic 
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Summary and Conclusions 127
The introduction of the thesis provided an overview of the role of transcatheter aortic 
valve implantation (TAVI) in current clinical practice with special focus on paravalvular 
aortic regurgitation (AR) and conduction disturbances. Also, detailed information were 
provided concerning the clinical role of multi-detector computed tomography (MDCT) 
to assist procedure planning and clarify the pathophysiology of procedural complica-
tions. There was additionally an overview of the so called “off-label” transcatheter 
aortic valve treatment for patients with failing bioprostheses and contraindications for 
conventional surgical treatment. Minimizing procedural complications and understand-
ing the challenges of widening current TAVI indications may help us to optimize the 
outcome of patients referred for TAVI.
PART I
This part of the thesis focused on role of MDCT to improve the management of patients 
undergoing TAVI. Clinical and demographical data in combination with information 
from the analysis of pre-operative and post-operative MDCT scans of patients undergo-
ing TAVI, were correlated with procedural complications. In Chapter 2 we sought the 
relation of the deployment of the Edwards SAPIEN frame in the aortic root and the pres-
ence of postprocedural paravalvular AR. Amongst various clinical and MDCT derived 
parameters, the difference between the MDCT derived maximum annulus diameter and 
the nominal diameter of the prosthesis and shallow position of the frame in the left 
ventricular outflow tract (LVOT) were independently related to significant paravalvular 
AR. These results underscore the association of prosthesis undersizing with paravalvular 
AR. In addition, a shallow position of the Edwards SAPIEN valve into the LVOT may lead 
to suboptimal cover area by the skirt of the frame, leading to paravalvular AR. Combina-
tion of pre- and post-implant MDCT was also used to define the pathophysiology of 
major conduction disorders following TAVI in Chapter 3. Amongst several anatomical, 
electrophysiological, MDCT and procedural parameters, implantation depth of the 
frame in the LVOT and overexpanding of the frame by >15% of the native aortic annulus 
area (measured on MDCT) were independently related with the need of pacemaker 
or new-onset LBBB. These results may be pathophysiologically explained by a deep 
implantation of the frame that may damage the atrio-ventricular node or left bundle 
branch while overexpansion of the frame can also induce compression forces into the 
left ventricular outflow tract. The clarification of the mechanisms responsible for new 
onset conduction disorders may have an impact on procedural planning and may 
also help the design of future transcatheter aortic valves. The clinical implications of 
positioning of the frame into the aortic root were further investigated with post-TAVI 
MDCT in Chapter 4. Specifically, the relation of the expanded frame with the ostia was 
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systematically investigated in 142 patients. Interestingly in 7.7% of patients there was a 
full overlap of the frame with any of the coronary ostia and in 35.9% of cases the frame 
overlapped the coronary ostia by >3 mm. Partly or full overlap of the coronary ostia 
by the frame was not related to post-operative troponin leak or to long-term occur-
rence and feasibility of new percutaneous coronary intervention. We have also shown 
that impingement of the coronary ostia by the frame is relatively rare and may be not 
systematically related to perioperative ischemia. Chapter 5 discusses the occurrence of 
early and late pericardial effusion after TAVI, a complication that remains barely evalu-
ated. New onset moderate pericardial effusion at 1 month after the procedure was diag-
nosed with echocardiography and MDCT in 2.5% of patients and only in cases treated 
with transapical TAVI. However, there were no documented clinical signs or symptoms of 
cardiac tamponate in any of the patients. It should be emphasised that there were some 
discrepancies in pericardial effusion grading between imaging modalities. The clinical 
significance of these findings is not clear.
PART II
This part of the thesis focuses on the outcome of specific populations of patients under-
going TAVI. Particularly, Chapter 6 discusses the outcome of patients with high baseline 
valvulo-arterial impedance (ZVa), an echocardiographic derived marker of global (val-
vular and arterial) afterload in aortic stenosis patients. Patients with baseline ZVa ≥5 
mmHg/mL/m2 had higher mortality rates compared to patients with lower ZVa values. 
Moreover baseline ZVa was independently associated with all-cause mortality at follow-
up. A higher baseline ZVa levels may be associated with advanced myocardial fibrosis 
and dysfunction. This measurement could be implemented in future TAVI risk scores, 
optimizing selection of patients that may benefit from the procedure. In Chapter 7 
there is a special focus on patients with significant mitral regurgitation undergoing TAVI. 
Severe mitral regurgitation is generally considered contraindication for TAVI. However, 
patients with severe aortic stenosis and concomitant significant mitral regurgitation 
deemed inoperable or at excessive surgical risk may still undergo TAVI as a last bailout 
treatment. Patients with mild or more mitral regurgitation were included and quantita-
tive analysis of mitral regurgitation evaluation was performed at baseline, pre-discharge 
and 12 months follow-up echocardiography. There was a significant acute post-operative 
reduction of mitral regurgitation in the overall population. Baseline effective orifice 
area and predominantly functional mitral regurgitation were independently related to 
acute pre-discharge improvement. These results underscore that TAVI candidates with 
significant mitral regurgitation and concomitant functional mitral valve pathology may 
not be excluded from TAVI. In Chapter 8 we evaluated the outcome of high operative 
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risk patients undergoing TAVI for failing bioprosthetic valves. This was the first direct 
comparison of a small group of patients with failing bioprosthesis in the aortic and 
mitral valve position treated with transcatheter valve implantation with a similar group 
of patients treated with redo cardiac surgery. Both groups were comparable in terms of 
baseline comorbidities, logistic Euroscore predicted surgical risk, functional status and 
left ventricular ejection fraction. After a median follow-up of 21 months survival was 
similar in both groups. TAVI is a minimally invasive procedure that may be a viable al-
ternative to redo cardiac surgery for elderly patients with failing bioprostheses deemed 
inoperable or at excessive surgical risk.
In conclusion, the number of TAVIs has exponentially increased over the last 10 years. 
Advances in technical aspects, learning curve and improved sizing of aortic annulus 
with 3-dimensional imaging techniques, particularly MDCT, have improved the results 
and have made possible the treatment of specific subgroups of patients who were 
considered initially not suited for TAVI (bicuspid aortic valves, failing bioprostheses). The 
role of MDCT in the development of TAVI has been crucial. Post-TAVI MDCT data has 
helped us to understand the underlying mechanisms of specific complications related 
to TAVI. The future of TAVI is promising with the development of new devices that may 
accommodate several aortic annulus and root anatomies, that are suited for aortic 
regurgitation and for failing bioprostheses. In this future, the role of imaging is pivotal 
and particularly, MDCT is one of the imaging techniques of choice due to its high spatial 
resolution, permitting the development of holograms that will help the interventionalist 
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In de introductie van dit proefschrift wordt een overzicht gegeven van de rol die 
transkatheter aortaklep implantatie (TAVI) in de huidige klinische praktijk vervult en 
hierbij als extra focus de complicaties paravalvulaire aortaklep insufficiëntie (AI) en post-
procedurele geleidingsstoornissen. Tevens wordt er gedetailleerd ingegaan op de rol 
die multi-detector computed tomography (MDCT) kan hebben in het plannen van de 
procedure en in het pathofysiologisch verklaren van complicaties. Daarnaast wordt hier 
ook nog een overzicht beschreven van het “off-label’’ gebruik van TAVI als behandeling 
voor patiënten met falende bioprosthese kunstkleppen welke wegens contra-indicatie 
niet chirurgisch vervangen kunnen worden. Het tot een minimum brengen van de pro-
cedurele complicaties en het beter begrijpen van de uitdagingen welke het verbreden 
van de TAVI-indicatie met zich mee brengt zou ons kunnen helpen de uitkomst van voor 
TAVI verwezen patiënten te verbeteren.
PART I
In dit deel van het proefschrift is gefocust op hoe het gebruik van MDCT het beleid 
van TAVI patiënten zou kunnen verbeteren. De informatie van pre- en post-operatieve 
MDCT scans werd gecombineerd met de klinische en demografische patiëntgegevens 
en vervolgens gecorreleerd aan complicaties. In Hoofdstuk 2 bestudeerden we de 
relatie tussen het ontplooien van het Edwards SAPIEN frame in de aortawortel en de 
post-procedurele aanwezigheid van paravalvulaire AI. Te midden van diverse klinische 
en MDCT parameters waren én het verschil tussen de maximale MDCT aorta annulus 
diameter en de nominale diameter van de prosthese én een ondiepe plaatsing van 
het frame in de linker kamer outflow tract (LKOT) onafhankelijk gerelateerd aan de 
aanwezigheid van significante paravalvulaire AI. Deze bevindingen benadrukken 
de associatie tussen het kiezen van een te kleine prosthese met de post-procedurele 
aanwezigheid van paravalvulaire AI. Daarnaast kan een te ondiepe plaatsing van de 
Edwards SAPIEN klep in de LKOT leiden tot suboptimale afdekking van de rand van het 
frame hetgeen ook tot paravalvulaire kleplekkage kan leiden. In Hoofdstuk 3 werden de 
pre- en postimplantatie MDCT’s gebruikt voor het ophelderen van de pathofysiologie 
van belangrijke post-procedurele geleidingsstoornissen. Te midden van diverse anato-
mische, elektrofysiologische, MDCT en procedurele parameters, waren de implantatie 
diepte van het frame in de LKOT en overexpansie van het frame met >15% ten opzichte 
van de oorspronkelijke aorta annulus oppervlakte (gemeten met MDCT) onafhankelijk 
gerelateerd aan de noodzaak voor een pacemaker of het ontstaan van een nieuw linker 
bundeltakblok. Pathofysiologisch zouden deze bevinden verklaard kunnen worden 
doordat een te diepe implantatie van het frame de AV knoop of de linker bundeltak kan 
beschadigen en ook overexpansie van het frame kan leiden tot compressie krachten 
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op de LKOT. Met het ophelderen van mechanismen die verantwoordelijk zijn voor het 
ontstaan van nieuwe geleidingsstoornissen kan de planning van de procedure worden 
verbeterd en kan wellicht ook het design van toekomstige TAVI prostheses worden 
gefaciliteerd. De klinische implicaties van de positie van het frame in de aortawortel 
werden verder onderzocht met post-TAVI MDCT in Hoofdstuk 4. Hier werd de relatie 
tussen het ontplooide frame en de ostia van de coronairen in 142 patiënten systematisch 
bestudeerd: in 7.7% van de patiënten overlapte het frame een van de coronair ostia vol-
ledig en in 35.9% van de patiënten werden de coronair ostia met meer dan 3 mm bedekt 
door het frame.
Zowel gedeeltelijke als volledige bedekking van de coronair ostia door het frame was 
niet gerelateerd aan post-procedurele troponine lekkage en op de lange termijn ook 
niet aan het verrichten van een dotterbehandeling of de mogelijkheid hiertoe. Hiernaast 
hebben we ook aangetoond dat inklemming van de coronair ostia door het frame relatief 
zeldzaam is en dat dit niet systematisch is gerelateerd aan post-procedurele ischemie. 
In Hoofdstuk 5 wordt ingegaan op het ontstaan van vroege en late pericard effusie 
na TAVI; een complicatie welke tot dusver nauwelijks bestudeerd is. De aanwezigheid 
van nieuwe, matige pericard effusie 1 maand na de procedure werd gediagnosticeerd 
in 2.5% van de patiënten met echocardiografie en MDCT en werd alleen gevonden in 
diegenen die transapicaal waren behandeld. In geen van de patiënten waren er echter 
gedocumenteerde tekenen of symptomen van een cardiale tamponade. Er moet wor-
den vermeld dat er wat discrepanties waren in het graderen van pericard effusie tussen 
de verschillende imaging modaliteiten. De klinische relevantie van deze bevindingen is 
niet duidelijk.
PART II
In dit deel van het proefschrift wordt de focus gelegd op de uitkomsten van specifieke 
patient populaties die TAVI ondergaan. Zo wordt in Hoofdstuk 6 ingegaan op de uit-
komsten van TAVI in patiënten met een hoge baseline valvulo-arteriele impedantie 
(ZVa); dit is een echocardiografische maat voor de globale –met zowel de klep als arte-
riële- afterload in patiënten met een aortaklep stenose. In patiënten met een baseline 
ZVa ≥5 mmHg/mL/m2 was de mortaliteitsfrequentie hoger dan in patiënten met lagere 
ZVa waarden. Bovendien was de baseline ZVa gedurende de follow-up onafhankelijk 
geassocieerd met mortaliteit door alle oorzaken. Een hogere ZVa waarde kan geas-
socieerd zijn met verder gevorderde myocardiale fibrose en dysfunctie. Deze meting 
zou in toekomstige TAVI risico-scores geïmplementeerd kunnen worden en dit zou de 
patient-selectie voor deze procedure ten goede kunnen komen. In Hoofdstuk 7 wordt 
de aandacht gevestigd op TAVI patiënten die ook significante mitralisklep insufficiëntie 
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hebben. In het algemeen wordt ernstige mitralisklep insufficiëntie als contra-indicatie 
voor TAVI beschouwd. Desondanks kunnen patiënten met een ernstige aortaklep ste-
nose en tevens een significante mitralisklep insufficiëntie die inoperabel worden geacht 
of waarbij er een excessief chirurgisch risico bestaat alsnog met TAVI worden behandeld 
als middel van laatste redding. Van patiënten met minimaal milde mitralisklep insuf-
ficiëntie werd de mitralisklep insufficiëntie kwantitatief geanalyseerd op de echocar-
diogrammen van aanvang, van voor het ontslag en op de echo van 12 maanden. In de 
gehele populatie was er post-procedureel acuut een significante vermindering van de 
mitralisklep insufficiëntie. Een functionele aard van de mitralisklep insufficiëntie en de 
baseline “effective orifice area” van de insufficiëntie waren onafhankelijk gerelateerd aan 
de acute verbetering op de echocardiogrammen voor het ontslag. Met deze resultaten 
wordt benadrukt dat TAVI kandidaten met significante mitralisklep insufficiëntie niet 
geëxcludeerd hoeven te worden voor het ondergaan van TAVI.
In Hoofdstuk 8 evalueerden we de uitkomsten van patiënten met een hoog chirur-
gisch risico die TAVI ondergingen wegens een falende bioprosthese kunstklep. Dit was de 
eerste directe vergelijking tussen een kleine groep patiënten met falende bioprostheses 
in aorta- en mitralisklep positie die behandeld was met TAVI met een vergelijkbare groep 
die behandeld was met redo chirurgie. Beide groepen waren vergelijkbaar in baseline 
co-morbiditeit, voorspeld chirurgisch risico zoals beoordeeld met de logistische Euro-
SCORE, functionele status en linker kamer ejectiefractie. Na een mediane follow-up van 
21 maanden was de overleving vergelijkbaar in beide groepen. Vanwege het minimaal 
invasieve karakter kan TAVI een geschikt alternatief zijn voor redo chirurgie in oudere 
patiënten met falende bioprostheses die inoperabel worden geacht of een excessief 
chirurgisch risico hebben. Concluderend is in de afgelopen 10 jaar het aantal verrichte 
TAVI’s exponentieel gegroeid. Technische vooruitgang, een leercurve en verbeteringen 
in het sizen van de aortaklep annulus met 3-dimensionale imaging technieken en dan 
met name met MDCT, hebben de resultaten van TAVI verbeterd en hebben het tevens 
mogelijk gemaakt dat specifieke patiënt groepen waarvoor TAVI initieel niet geschikt 
geacht werd (bicuspide aortakleppen, falende bioprostheses), behandeld kunnen wor-
den. MDCT heeft een cruciale rol gespeeld in de ontwikkeling van TAVI. Post-TAVI MDCT 
heeft ons geholpen om de onderliggende mechanismen van specifieke complicaties 
gerelateerd aan TAVI te begrijpen. Met de ontwikkeling van nieuwe devices die kunnen 
accommoderen in diverse aortaklep annulus en aortawortel anatomieën en devices die 
geschikt zijn voor de behandeling van AI en falende bioprosthese kunstkleppen is de 
toekomst van TAVI veelbelovend. Binnen deze toekomst blijft de rol van beeldvorming 
cruciaal. Met de grote ruimtelijke resolutie van MDCT wordt de ontwikkeling van ho-
logrammen gefaciliteerd en hiermee kan de interventionalist geholpen worden in de 
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